

BioMed Realty Trust Inc  
Form 10-Q  
July 30, 2009

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 10-Q  
QUARTERLY REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934  
For the quarterly period ended June 30, 2009  
Commission File Number: 1-32261  
BIOMED REALTY TRUST, INC.  
(Exact name of registrant as specified in its charter)**

**Maryland**  
*(State or other jurisdiction of  
incorporation or organization)*

**20-1142292**  
*(I.R.S. Employer  
Identification No.)*

**17190 Bernardo Center Drive  
San Diego, California**  
*(Address of Principal Executive Offices)*

**92128**  
*(Zip Code)*

**(858) 485-9840**

*(Registrant's telephone number, including area code)*

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of outstanding shares of the registrant's common stock, par value \$0.01 per share, as of July 29, 2009 was 98,115,525.

**BIOMED REALTY TRUST, INC.**  
**FORM 10-Q QUARTERLY REPORT**  
**FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2009**  
**TABLE OF CONTENTS**

|  | <b>Page</b> |
|--|-------------|
| <b><u>PART I FINANCIAL INFORMATION</u></b>   |             |
| <b><u>Item 1 Consolidated Financial Statements</u></b>   | 3           |
| <u>Consolidated Balance Sheets as of June 30, 2009 (Unaudited) and December 31, 2008 (Unaudited)</u>                         | 3           |
| <u>Consolidated Statements of Income for the three and six months ended June 30, 2009 and 2008 (Unaudited)</u>               | 4           |
| <u>Consolidated Statements of Equity for the six months ended June 30, 2009 (Unaudited)</u>                                  | 5           |
| <u>Consolidated Statements of Comprehensive Income for the three and six months ended June 30, 2009 and 2008 (Unaudited)</u> | 6           |
| <u>Consolidated Statements of Cash Flows for the six months ended June 30, 2009 and 2008 (Unaudited)</u>                     | 7           |
| <u>Notes to Consolidated Financial Statements (Unaudited)</u>  | 8           |
| <b><u>Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>                   | 29          |
| <b><u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u></b>  | 40          |
| <b><u>Item 4 Controls and Procedures</u></b>   | 41          |
| <b><u>PART II OTHER INFORMATION</u></b>  |             |
| <b><u>Item 1 Legal Proceedings</u></b>   | 42          |
| <b><u>Item 1A Risk Factors</u></b>   | 42          |
| <b><u>Item 2 Unregistered Sales of Equity Securities and Use of Proceeds</u></b>   | 42          |
| <b><u>Item 3 Defaults Upon Senior Securities</u></b>   | 42          |
| <b><u>Item 4 Submission of Matters to a Vote of Security Holders</u></b>   | 43          |
| <b><u>Item 5 Other Information</u></b>   | 43          |
| <b><u>Item 6 Exhibits</u></b>  | 43          |
| <b><u>SIGNATURES</u></b>   | 44          |

Exhibit 31.1

Exhibit 31.2

Exhibit 32.1

**Table of Contents****PART I FINANCIAL INFORMATION****ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS****BIOMED REALTY TRUST, INC.  
CONSOLIDATED BALANCE SHEETS****(In thousands, except share data)****(Unaudited)**

|   | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008<br/>(Revised)</b> |
|---|--------------------------|--|
| <b>ASSETS</b>   |                          |  |
| Investments in real estate, net   | \$ 2,994,072             | \$ 2,960,429                               |
| Investments in unconsolidated partnerships  | 49,243                   | 18,173                                     |
| Cash and cash equivalents   | 34,101                   | 21,422                                     |
| Restricted cash   | 15,638                   | 7,877                                      |
| Accounts receivable, net  | 10,178                   | 9,417                                      |
| Accrued straight-line rents, net  | 69,046                   | 58,138                                     |
| Acquired above-market leases, net   | 3,688                    | 4,329                                      |
| Deferred leasing costs, net   | 90,472                   | 101,519                                    |
| Deferred loan costs, net  | 8,535                    | 9,754                                      |
| Other assets  | 36,939                   | 38,256                                     |
| <b>Total assets</b>   | <b>\$ 3,311,912</b>      | <b>\$ 3,229,314</b>                        |
| <b>LIABILITIES AND EQUITY</b>   |                          |  |
| Mortgage notes payable, net   | \$ 717,764               | \$ 353,161                                 |
| Secured construction loan   |                          | 507,128                                    |
| Secured term loan   | 250,000                  | 250,000                                    |
| Exchangeable senior notes, net  | 103,077                  | 122,043                                    |
| Unsecured line of credit  | 292,404                  | 108,767                                    |
| Security deposits   | 7,660                    | 7,623                                      |
| Dividends and distributions payable   | 15,383                   | 32,445                                     |
| Accounts payable, accrued expenses, and other liabilities   | 66,406                   | 66,821                                     |
| Derivative instruments  | 17,910                   | 126,091                                    |
| Acquired below-market leases, net   | 13,550                   | 17,286                                     |
| <b>Total liabilities</b>  | <b>1,484,154</b>         | <b>1,591,365</b>                           |
| Equity:   |                          |  |
| Stockholders' equity:   |                          |  |
| Preferred stock, \$.01 par value, 15,000,000 shares authorized: 7.375% Series A cumulative redeemable preferred stock, \$230,000,000 liquidation preference (\$25.00 per share), 9,200,000 shares issued and outstanding at June 30, 2009 and December 31, 2008 | 222,413                  | 222,413                                    |
| Common stock, \$.01 par value, 150,000,000 and 100,000,000 shares authorized, 98,118,639 and 80,757,421 shares issued and outstanding at June 30, 2009 and December 31, 2008, respectively  | 981                      | 808  |
| Additional paid-in capital  | 1,833,026                | 1,661,009                                  |
| Accumulated other comprehensive loss  | (91,525)                 | (112,126)                                  |
| Dividends in excess of earnings   | (147,306)                | (146,536)                                  |

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

|                                     |                     |                     |
|-------------------------------------|---------------------|---------------------|
| Total stockholders' equity          | 1,817,589           | 1,625,568           |
| Noncontrolling interests            | 10,169              | 12,381              |
| Total equity                        | 1,827,758           | 1,637,949           |
| <b>Total liabilities and equity</b> | <b>\$ 3,311,912</b> | <b>\$ 3,229,314</b> |

See accompanying notes to consolidated financial statements.

**Table of Contents**

**BIOMED REALTY TRUST, INC.**  
**CONSOLIDATED STATEMENTS OF INCOME**  
(In thousands, except share data)  
(Unaudited)

|   | For the Three Months<br>Ended June 30, |                   | For the Six Months<br>Ended June 30, |                   |
|---|--|-------------------|--------------------------------------|-------------------|
|   | 2009                                   | 2008<br>(Revised) | 2009                                 | 2008<br>(Revised) |
| Revenues:   |  |                   |                                      |                   |
| Rental  | \$ 65,716                              | \$ 54,223         | \$ 134,135                           | \$ 104,565        |
| Tenant recoveries   | 17,189                                 | 15,804            | 38,270                               | 32,386            |
| Other income  | 3,175                                  | 744               | 7,626                                | 1,178             |
| Total revenues  | 86,080                                 | 70,771            | 180,031                              | 138,129           |
| Expenses:   |  |                   |                                      |                   |
| Rental operations   | 14,661                                 | 13,454            | 36,813                               | 27,318            |
| Real estate taxes   | 7,613                                  | 4,915             | 14,846                               | 10,185            |
| Depreciation and amortization                               | 24,501                                 | 19,331            | 51,813                               | 37,018            |
| General and administrative                                  | 5,126                                  | 5,645             | 10,407                               | 11,839            |
| Total expenses  | 51,901                                 | 43,345            | 113,879                              | 86,360            |
| Income from operations                                      | 34,179                                 | 27,426            | 66,152                               | 51,769            |
| Equity in net (loss)/ income of unconsolidated partnerships | (465)                                  | 43                | (766)                                | (130)             |
| Interest income   | 101                                    | 106               | 164                                  | 261               |
| Interest expense  | (12,875)                               | (9,009)           | (24,955)                             | (16,181)          |
| Gain on derivative instruments                              | 360                                    |                   | 303                                  |                   |
| Gain on extinguishment of debt                              | 1,781                                  |                   | 6,152                                |                   |
| Net income  | 23,081                                 | 18,566            | 47,050                               | 35,719            |
| Net income attributable to noncontrolling interests         | (645)                                  | (620)             | (1,350)                              | (1,202)           |
| Net income attributable to Company                          | 22,436                                 | 17,946            | 45,700                               | 34,517            |
| Preferred stock dividends                                   | (4,241)                                | (4,241)           | (8,481)                              | (8,481)           |
| Net income available to common stockholders                 | \$ 18,195                              | \$ 13,705         | \$ 37,219                            | \$ 26,036         |
| Net income per share available to common stockholders:      |  |                   |                                      |                   |
| Basic and diluted earnings per share                        | \$ 0.20                                | \$ 0.19           | \$ 0.44                              | \$ 0.38           |
| Weighted-average common shares outstanding:                 |  |                   |                                      |                   |
| Basic   | 88,503,295                             | 70,094,003        | 84,403,582                           | 67,722,258        |

|         |            |            |            |            |
|---------|------------|------------|------------|------------|
| Diluted | 92,615,935 | 73,811,597 | 88,580,072 | 71,418,266 |
|---------|------------|------------|------------|------------|

See accompanying notes to consolidated financial statements.



Table of Contents

**BIOMED REALTY TRUST, INC.**  
**CONSOLIDATED STATEMENTS OF EQUITY**  
(In thousands, except share data)  
(Unaudited)

|   | Series A<br>Preferred<br>Stock | Common<br>Shares | Common<br>Stock<br>Amount | Accumulated                      |   |  | Total<br>Stockholder<br>Equity | Noncontrolling<br>Interests | Total<br>Equity |
|---|--------------------------------|------------------|---------------------------|----------------------------------|---|--|--------------------------------|-----------------------------|-----------------|
|   |                                |                  |                           | Additional<br>Paid-In<br>Capital | Other<br>Comprehensive<br>(Loss)/Income | Dividends<br>in<br>Excess of<br>Earnings |                                |                             |                 |
| <b>Balance at<br/>December 31,<br/>2008<br/>(Revised)</b>             | \$ 222,413                     | 80,757,421       | \$ 808                    | \$ 1,661,009                     | \$ (112,126)                            | \$ (146,536)                             | \$ 1,625,568                   | \$ 12,381                   | \$ 1,637,949    |
| Net proceeds<br>from sale of<br>common stock                          |                                | 16,754,854       | 168                       | 166,758                          |   |  | 166,926                        |                             | 166,926         |
| Net issuances<br>of unvested<br>restricted<br>common stock            |                                | 344,554          | 3                         | (33)                             |   |  | (30)                           |                             | (30)            |
| Conversion of<br>operating<br>partnership<br>units to<br>common stock |                                | 261,810          | 2                         | 1,869                            |   |  | 1,871                          | (2,212)                     | (341)           |
| Vesting of<br>share-based<br>awards                                   |                                |                  |                           | 2,787                            |   |  | 2,787                          |                             | 2,787           |
| Allocation of<br>equity to<br>noncontrolling<br>interests             |                                |                  |                           | 636                              |   |  | 636                            | (636)                       |                 |
| Common stock<br>dividends   |                                |                  |                           |                                  |   | (37,989)                                 | (37,989)                       |                             | (37,989)        |
| Net income  |                                |                  |                           |                                  |   | 45,700                                   | 45,700                         | 1,350                       | 47,050          |
| Preferred stock<br>dividends  |                                |                  |                           |                                  |   | (8,481)                                  | (8,481)                        |                             | (8,481)         |
| OP unit<br>distributions  |                                |                  |                           |                                  |   |  |                                | (1,475)                     | (1,475)         |
| Unrealized<br>gain on<br>marketable<br>securities                     |                                |                  |                           |                                  |   | 1,680                                    | 1,680                          | 60                          | 1,740           |
| Unrealized<br>gains on<br>derivative<br>instruments                   |                                |                  |                           |                                  |   | 18,921                                   | 18,921                         | 701                         | 19,622          |

**Balance at**  
**June 30, 2009** \$ 222,413 98,118,639 \$ 981 \$ 1,833,026 \$ (91,525) \$(147,306) \$ 1,817,589 \$ 10,169 \$ 1,827,758

See accompanying notes to consolidated financial statements.

Table of Contents

**BIOMED REALTY TRUST, INC.**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
(In thousands)  
(Unaudited)

|  | <b>Three Months Ended</b> |                  | <b>Six Months Ended</b> |                  |
|--|---------------------------|------------------|-------------------------|------------------|
|  | <b>June 30,</b>           |                  | <b>June 30,</b>         |                  |
|  | <b>2009</b>               | <b>2008</b>      | <b>2009</b>             | <b>2008</b>      |
|  |                           | <b>(Revised)</b> |                         | <b>(Revised)</b> |
| Net income available to common stockholders and noncontrolling interests | \$ 18,840                 | \$ 14,325        | \$ 38,569               | \$ 27,238        |
| Other comprehensive income/(loss):                                       |                           |                  |                         |                  |
| Unrealized gain/(loss) on derivative instruments                         | 8,671                     | 30,565           | 21,458                  | (1,502)          |
| Equity in other comprehensive income of unconsolidated partnerships      | (23)                      | 312              | (236)                   | 312              |
| Deferred settlement payments derivative instruments, net                 | (725)                     | (1,831)          | (1,600)                 | (2,826)          |
| Unrealized gain on marketable securities                                 | 1,170                     |                  | 1,740                   |                  |
| Total other comprehensive income/(loss)                                  | 9,093                     | 29,046           | 21,362                  | (4,016)          |
| Comprehensive income   | 27,933                    | 43,371           | 59,931                  | 23,222           |
| Comprehensive (income)/loss attributable to noncontrolling interests     | (949)                     | 1,844            | (2,111)                 | 944              |
| Comprehensive income attributable to common stockholders                 | \$ 26,984                 | \$ 45,215        | \$ 57,820               | \$ 24,166        |

See accompanying notes to consolidated financial statements.

**Table of Contents**

**BIOMED REALTY TRUST, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(In thousands)  
(Unaudited)

|   | <b>Six Months Ended</b> |                  |
|---|-------------------------|------------------|
|   | <b>June 30,</b>         |                  |
|   | <b>2009</b>             | <b>2008</b>      |
|   |                         | <b>(Revised)</b> |
| Operating activities:   |                         |                  |
| Net income  | \$ 47,050               | \$ 35,719        |
| Adjustments to reconcile net income to net cash provided by operating activities:                   |                         |                  |
| Gain on extinguishment of debt  | (6,152)                 |                  |
| Gain on derivative instruments  | (303)                   |                  |
| Depreciation and amortization   | 51,813                  | 37,018           |
| Allowance for doubtful accounts   | 3,824                   | 39               |
| Revenue reduction attributable to acquired above-market leases                                      | 641                     | 728              |
| Revenue recognized related to acquired below-market leases  | (5,114)                 | (3,006)          |
| Revenue reduction attributable to lease incentives  | 637                     | 290              |
| Compensation expense related to restricted common stock and LTIP units                              | 2,787                   | 2,839            |
| Amortization of deferred loan costs   | 2,363                   | 1,524            |
| Amortization of debt premium on mortgage notes payable  | (920)                   | (397)            |
| Amortization of debt discount on exchangeable senior notes  | 936                     | 1,345            |
| Loss from unconsolidated partnerships   | 766                     | 130              |
| Distributions representing return on capital from unconsolidated partnerships                       | 61                      | 306              |
| Changes in operating assets and liabilities:  |                         |                  |
| Restricted cash   | (7,761)                 | 876              |
| Accounts receivable   | (1,230)                 | 1,041            |
| Accrued straight-line rents   | (14,263)                | (10,582)         |
| Deferred leasing costs  | (4,955)                 | (4,332)          |
| Other assets  | 2,975                   | (1,422)          |
| Security deposits   | 37                      | 521              |
| Accounts payable, accrued expenses and other liabilities  | (507)                   | (10,299)         |
| Net cash provided by operating activities   | 72,685                  | 52,338           |
| Investing activities:   |                         |                  |
| Purchases of interests in and additions to investments in real estate and related intangible assets | (69,369)                | (130,827)        |
| Distributions representing return of capital from unconsolidated partnerships                       |                         | 1,373            |
| Contributions to unconsolidated partnerships, net   | (32,135)                | (67)             |
| Receipts of master lease payments   |                         | 103              |
| Additions to non-real estate assets   | (31)                    | (5,038)          |
| Net cash used in investing activities   | (101,535)               | (134,456)        |
| Financing activities:   |                         |                  |
| Proceeds from common stock offering   | 174,250                 | 156,289          |
| Payment of common stock offering costs  | (7,324)                 | (6,594)          |

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

|   |           |           |
|---|-----------|-----------|
| Payment of deferred loan costs  | (1,735)   |           |
| Unsecured line of credit proceeds   | 350,617   | 91,801    |
| Unsecured line of credit payments   | (166,980) | (149,538) |
| Mortgage loan proceeds  | 368,000   |           |
| Principal payments on mortgage notes payable  | (2,477)   | (4,992)   |
| Repurchases of exchangeable senior notes  | (12,605)  |           |
| Settlement of derivative instruments  | (86,482)  |           |
| Secured construction loan proceeds  |           | 58,837    |
| Secured construction loan payments  | (507,128) |           |
| Deferred settlement payments, net on interest rate swaps  | (1,600)   | (2,826)   |
| Distributions to operating partnership unit and LTIP unit holders   | (2,277)   | (2,200)   |
| Dividends paid to common stockholders   | (54,249)  | (42,299)  |
| Dividends paid to preferred stockholders  | (8,481)   | (8,482)   |
| Net cash provided by financing activities   | 41,529    | 89,996    |
| Net increase in cash and cash equivalents   | 12,679    | 7,878     |
| Cash and cash equivalents at beginning of period  | 21,422    | 13,479    |
| Cash and cash equivalents at end of period  | \$ 34,101 | \$ 21,357 |
| Supplemental disclosure of cash flow information:   |           |           |
| Cash paid during the period for interest (net of amounts capitalized of \$7,601 and \$26,908, respectively) | \$ 21,734 | \$ 15,768 |
| Supplemental disclosure of non-cash investing and financing activities:                                     |           |           |
| Accrual for preferred stock dividends declared  | \$ 4,241  | \$ 4,241  |
| Accrual for common stock dividends declared   | 10,793    | 24,025    |
| Accrual for distributions declared for operating partnership unit and LTIP unit holders                     | 349       | 1,174     |
| Accrued additions to real estate and related intangible assets  | 26,565    | 44,926    |

See accompanying notes to consolidated financial statements.

**Table of Contents**

**BIOMED REALTY TRUST, INC.**  
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. Organization and Description of Business**

BioMed Realty Trust, Inc., a Maryland corporation (the Company), was incorporated in Maryland on April 30, 2004. On August 11, 2004, the Company commenced operations after completing its initial public offering. The Company operates as a fully integrated, self-administered and self-managed real estate investment trust (REIT) focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry principally through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership (the Operating Partnership). The Company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey.

**2. Basis of Presentation and Summary of Significant Accounting Policies**

The accompanying interim financial statements are unaudited, but have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in conjunction with the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all the disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments and eliminations, consisting of normal recurring adjustments necessary for a fair presentation of the financial statements for these interim periods have been recorded. In preparing the accompanying interim financial statements, the Company has evaluated the potential occurrence of subsequent events through July 30, 2009, the date at which the financial statements were issued. These financial statements should be read in conjunction with the audited consolidated financial statements and notes therein included in the Company's annual report on Form 10-K for the year ended December 31, 2008.

***Principles of Consolidation***

The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, partnerships and limited liability companies it controls, and variable interest entities for which the Company has determined itself to be the primary beneficiary. All material intercompany transactions and balances have been eliminated. The Company consolidates entities the Company controls and records a noncontrolling interest for the portions not owned by the Company. Control is determined, where applicable, by the sufficiency of equity invested and the rights of the equity holders, and by the ownership of a majority of the voting interests, with consideration given to the existence of approval or veto rights granted to the minority stockholder. If the minority stockholder holds substantive participating rights, it overcomes the presumption of control by the majority voting interest holder. In contrast, if the minority stockholder simply holds protective rights (such as consent rights over certain actions), it does not overcome the presumption of control by the majority voting interest holder.

***Investments in Partnerships***

The Company evaluates its investments in limited liability companies and partnerships under Financial Accounting Standards Board (FASB) Interpretation No. 46 (revised December 2003), *Consolidation of Variable Interest Entities* (FIN 46R), an interpretation of Accounting Research Bulletin No. 51, *Consolidated Financial Statements*. FIN 46R provides guidance on the identification of entities for which control is achieved through means other than voting rights (variable interest entities) and the determination of which business enterprise should consolidate the variable interest entity (the primary beneficiary). Generally, FIN 46R applies when either (1) the equity investors (if any) lack one or more of the essential characteristics of a controlling financial interest, (2) the equity investment at risk is insufficient to finance that entity's activities without additional subordinated financial support or (3) the equity investors have voting rights that are not proportionate to their economic interests and the activities of the entity involve or are conducted on behalf of an investor with a disproportionately small voting interest.

If FIN 46R does not apply, the Company considers Emerging Issues Task Force (EITF) Issue No. 04-5, *Determining Whether a General Partner, or the General Partners as a Group, Controls a Limited Partnership or Similar Entity When the Limited Partners Have Certain Rights* (EITF 04-5), which provides guidance in determining whether a

general partner controls a limited partnership. EITF 04-5 states that the general partner in a limited partnership is presumed to control that limited partnership. The presumption may be overcome if the limited partners have either (1) the substantive ability to dissolve the limited partnership or otherwise remove the general partner without cause or (2) substantive participating rights, which provide the limited partners with the ability to effectively participate in significant decisions that would be expected to be made in the ordinary course of the limited partnership's business and thereby preclude the general partner from exercising unilateral control over the partnership. If the criteria in EITF 04-5 are met and the Company is the general partner or the managing member, as applicable, the consolidation of the partnership or limited liability company is required.

**Table of Contents**

Except for investments that are consolidated in accordance with FIN 46R or EITF 04-5, the Company accounts for investments in entities over which it exercises significant influence, but does not control, under the equity method of accounting. These investments are recorded initially at cost and subsequently adjusted for equity in earnings and cash contributions and distributions. Under the equity method of accounting, the Company's net equity in the investment is reflected in the consolidated balance sheets and its share of net income or loss is included in the Company's consolidated statements of income.

On a periodic basis, management assesses whether there are any indicators that the carrying value of the Company's investments in unconsolidated partnerships or limited liability companies may be impaired on a more than temporary basis. An investment is impaired only if management's estimate of the fair-value of the investment (based on estimated future discounted cash flows) is less than the carrying value of the investment on a more than temporary basis. To the extent impairment has occurred, the loss is measured as the excess of the carrying value of the investment over the fair-value of the investment. Management does not believe that the value of any of the Company's unconsolidated investments in partnerships or limited liability companies was impaired as of June 30, 2009.

***Investments in Real Estate***

Investments in real estate, net consists of the following (in thousands):

|                            | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008<br/>(Revised)</b> |
|----------------------------|--------------------------|--|
| Land                       | \$ 374,468               | \$ 347,878                                 |
| Land under development     | 42,933                   | 69,529                                     |
| Buildings and improvements | 2,306,668                | 2,104,072                                  |
| Construction in progress   | 296,013                  | 439,221                                    |
| Tenant improvements        | 172,987                  | 161,839                                    |
|                            | 3,193,069                | 3,122,539                                  |
| Accumulated depreciation   | (198,997)                | (162,110)                                  |
|                            | <b>\$ 2,994,072</b>      | <b>\$ 2,960,429</b>                        |

On February 24, 2009, the Company paid \$15.0 million upon completion of an expansion of an existing building located on the Company's 6114-6154 Nancy Ridge Drive property pursuant to the purchase and sale agreement for the original acquisition of the property in May 2007. In connection with the transaction, the Company recognized a below-market lease intangible liability related to the contractual lease rate on the additional premises of approximately \$1.4 million.

***Impairment of Long-Lived Assets and Long-Lived Assets to be Disposed***

The Company reviews long-lived assets and certain identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If estimated future undiscounted cash flows (excluding interest charges) expected to result from a long-lived asset's use and eventual disposition are insufficient to recover the carrying value of the long-lived asset, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair-value of the property. The Company is required to make subjective assessments as to whether there are impairments in the values of its investments in long-lived assets, including estimates of future cash flows, considering factors such as expected future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. These assessments have a direct impact on the Company's net income because recording an impairment loss results in an immediate negative adjustment to net income. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. Although the Company's strategy is to hold its properties over the long-term, if the Company's strategy changes or market conditions otherwise dictate an earlier sale date, an impairment loss may be recognized to



reduce the property to the lower of the carrying amount or fair-value, and such loss could be material. If the Company determines that impairment has occurred, the affected assets must be reduced to their fair-value. As of and through June 30, 2009, no assets have been identified as impaired and no such impairment losses have been recognized.

**Table of Contents****Deferred Leasing Costs**

Leasing commissions and other direct costs associated with new or renewal lease activity are recorded at cost and amortized on a straight-line basis over the terms of the respective leases, with remaining terms ranging from less than one year to approximately 15 years as of June 30, 2009. Deferred leasing costs also include the net carrying value of acquired in-place leases and acquired management agreements.

Deferred leasing costs, net at June 30, 2009 consisted of the following (in thousands):

|   | <b>Balance at<br/>June 30,<br/>2009</b> | <b>Accumulated<br/>Amortization</b> | <b>Net</b>       |
|---|---|-------------------------------------|------------------|
| Acquired in-place leases                | \$ 168,390                              | \$ (104,332)                        | \$ 64,058        |
| Acquired management agreements          | 12,921                                  | (9,883)                             | 3,038            |
| Deferred leasing and other direct costs | 30,152                                  | (6,776)                             | 23,376           |
|   | <b>\$ 211,463</b>                       | <b>\$ (120,991)</b>                 | <b>\$ 90,472</b> |

Deferred leasing costs, net at December 31, 2008 consisted of the following (in thousands):

|   | <b>Balance at<br/>December 31,<br/>2008</b> | <b>Accumulated<br/>Amortization</b> | <b>Net</b>        |
|---|---|-------------------------------------|-------------------|
| Acquired in-place leases                | \$ 168,390                                  | \$ (92,072)                         | \$ 76,318         |
| Acquired management agreements          | 12,921                                      | (8,602)                             | 4,319             |
| Deferred leasing and other direct costs | 26,364                                      | (5,482)                             | 20,882            |
|   | <b>\$ 207,675</b>                           | <b>\$ (106,156)</b>                 | <b>\$ 101,519</b> |

**Revenue Recognition**

The Company commences revenue recognition on its leases based on a number of factors. In most cases, revenue recognition under a lease begins when the lessee takes possession of or controls the physical use of the leased asset. Generally, this occurs on the lease commencement date. In determining what constitutes the leased asset, the Company evaluates whether the Company or the lessee is the owner, for accounting purposes, of the tenant improvements. If the Company is the owner, for accounting purposes, of the tenant improvements, then the leased asset is the finished space and revenue recognition begins when the lessee takes possession of the finished space, typically when the improvements are substantially complete. If the Company concludes that it is not the owner, for accounting purposes, of the tenant improvements (the lessee is the owner), then the leased asset is the unimproved space and any tenant improvement allowances funded under the lease are treated as lease incentives which reduce revenue recognized over the term of the lease. In these circumstances, the Company begins revenue recognition when the lessee takes possession of the unimproved space for the lessee to construct improvements. The determination of who is the owner, for accounting purposes, of the tenant improvements determines the nature of the leased asset and when revenue recognition under a lease begins. The Company considers a number of different factors to evaluate whether it or the lessee is the owner of the tenant improvements for accounting purposes. These factors include:

- whether the lease stipulates how and on what a tenant improvement allowance may be spent;
- whether the tenant or landlord retains legal title to the improvements;
- the uniqueness of the improvements;
- the expected economic life of the tenant improvements relative to the length of the lease;
- the responsible party for construction cost overruns; and
- who constructs or directs the construction of the improvements.

The determination of who owns the tenant improvements, for accounting purposes, is subject to significant judgment. In making that determination, the Company considers all of the above factors. However, no one factor is determinative in reaching a conclusion.

**Table of Contents**

All leases are classified as operating leases and minimum rents are recognized on a straight-line basis over the term of the related lease. The excess of rents recognized over amounts contractually due pursuant to the underlying leases are included in accrued straight-line rents on the accompanying consolidated balance sheets and contractually due but unpaid rents are included in accounts receivable. Existing leases at acquired properties are reviewed at the time of acquisition to determine if contractual rents are above or below current market rents for the acquired property. An identifiable lease intangible asset or liability is recorded based on the present value (using a discount rate that reflects the risks associated with the acquired leases) of the difference between (1) the contractual amounts to be paid pursuant to the in-place leases and (2) the Company's estimate of the fair market lease rates for the corresponding in-place leases at acquisition, measured over a period equal to the remaining non-cancelable term of the leases and any fixed-rate renewal periods (based on the Company's assessment of the likelihood that the renewal periods will be exercised). The capitalized above-market lease values are amortized as a reduction of rental income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values are amortized as an increase to rental income over the remaining non-cancelable terms of the respective leases and any fixed-rate renewal periods, if applicable. If a tenant abandons its space or terminates its lease prior to the contractual termination of the lease and no rental payments are being made on the lease, any unamortized balance of the related intangible will be written off.

Acquired above-market leases, net consisted of the following (in thousands):

|                              | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008</b> |
|------------------------------|--------------------------|------------------------------|
| Acquired above-market leases | \$ 12,729                | \$ 12,729                    |
| Accumulated amortization     | (9,041)                  | (8,400)                      |
|                              | \$ 3,688                 | \$ 4,329                     |

Acquired below-market leases, net consisted of the following (in thousands):

|                              | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008</b> |
|------------------------------|--------------------------|------------------------------|
| Acquired below-market leases | \$ 39,339                | \$ 37,961                    |
| Accumulated amortization     | (25,789)                 | (20,675)                     |
|                              | \$ 13,550                | \$ 17,286                    |

Lease incentives, net, which is included in other assets on the accompanying consolidated balance sheets, consisted of the following (in thousands):

|                          | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008</b> |
|--------------------------|--------------------------|------------------------------|
| Lease incentives         | \$ 11,920                | \$ 11,698                    |
| Accumulated amortization | (2,848)                  | (2,211)                      |
|                          | \$ 9,072                 | \$ 9,487                     |

Substantially all rental operations expenses, consisting of real estate taxes, insurance and common area maintenance costs, are subject to recovery from tenants under the terms of lease agreements. Amounts recovered are dependent on several factors, including occupancy and lease terms. Revenues are recognized in the period the expenses are incurred. The reimbursements are recognized and presented in accordance with EITF 99-19, *Reporting Revenue Gross as a Principal versus Net as an Agent* ( EITF 99-19 ). EITF 99-19 requires that these reimbursements be recorded gross, as

the Company is generally the primary obligor with respect to purchasing goods and services from third-party suppliers, has discretion in selecting the supplier and bears the credit risk.

**Table of Contents**

Lease termination fees are recognized in other revenue when the related leases are canceled, the amounts to be received are fixed and determinable and collectability is assured, and when the Company has no continuing obligation to provide services to such former tenants. The amortization of the related straight-line rent receivable, tenant recoveries and remaining other tangible and intangible assets corresponding to the lease terminations is accelerated to the termination date as a charge to their respective line items. The effect of lease terminations for the three and six months ended June 30, 2009 and 2008 was as follows:

|                                  | <b>Three Months Ended</b> |             | <b>Six Months Ended</b> |             |
|----------------------------------|---------------------------|-------------|-------------------------|-------------|
|                                  | <b>June 30,</b>           |             | <b>June 30,</b>         |             |
|                                  | <b>2009</b>               | <b>2008</b> | <b>2009</b>             | <b>2008</b> |
| Rental revenues                  | \$                        | \$          | \$ 2,619                | \$          |
| Other revenue                    |                           | 2,643       | 6,543                   |             |
| Total revenue                    |                           | 2,643       | 9,162                   |             |
| Rental operations expense        |                           | 520         | 4,204                   |             |
| Depreciation and amortization    |                           | 325         | 4,005                   |             |
| Total expenses                   |                           | 845         | 8,209                   |             |
| Net effect of lease terminations | \$                        | 1,798       | \$                      | 953         |

The Company maintains an allowance for doubtful accounts for estimated losses resulting from the inability of tenants to make required rent and tenant recovery payments or defaults. The Company may also maintain an allowance for accrued straight-line rents and amounts due from lease terminations based on an assessment of the collectability of the balance.

**Investments**

The Company, through its Operating Partnership, holds equity investments in certain publicly-traded companies and privately-held companies primarily involved in the life science industry. The Company may accept equity investments from tenants in lieu of cash rents, as prepaid rent pursuant to the execution of a lease, or as additional consideration for a lease termination. All of the Company's investments in publicly-traded companies are considered available-for-sale in accordance with Statement of Financial Accounting Standards ( SFAS ) No. 115, *Accounting for Certain Investments in Debt and Equity Securities* ( SFAS 115 ), and are recorded at fair-value pursuant to SFAS No. 157, *Fair Value Measurements* ( SFAS 157 ). The fair-value of the Company's equity investments in publicly-traded companies is determined based upon the closing trading price of the equity security as of the balance sheet date, with unrealized gains and losses shown as a separate component of stockholders' equity. The classification of investments under SFAS 115 is determined at the time each investment is made, and such determination is reevaluated at each balance sheet date. The cost of investments sold is determined by the specific identification method, with net realized gains and losses included in other income. Investments in privately-held companies are generally accounted for under the cost method because we do not influence any operating or financial policies of the companies in which we invest. For all investments, if a decline in the fair-value of an investment below its carrying value is determined to be other-than-temporary, such investment is written down to its estimated fair-value with a non-cash charge to earnings. The factors that the Company considers in making these assessments include, but are not limited to, market prices, market conditions, available financing, prospects for favorable or unfavorable clinical trial results, new product initiatives and new collaborative agreements.

Investments, which are included in other assets on the accompanying consolidated balance sheets, consisted of the following (in thousands):

|                                       | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008</b> |
|---------------------------------------|--------------------------|------------------------------|
| Equity securities, initial cost basis | \$ 620                   | \$                           |
| Unrealized gain                       | 1,740                    |                              |
| Equity securities, fair-value         | \$ 2,360                 | \$                           |

***Share-Based Payments***

SFAS No. 123 (revised 2004), *Share-Based Payment*, requires that all share-based payments to employees be recognized in the income statement based on their fair-value. The fair-value is recorded based on the market value of the common stock on the grant date and is amortized to general and administrative expense and rental operations expense over the relevant service period, adjusted for anticipated forfeitures. Through June 30, 2009, the Company had only awarded restricted stock and long-term incentive plan ( LTIP ) unit grants under its incentive award plan (see Note 7), which are valued based on the closing market price of the underlying common stock on the date of grant, and had not granted any stock options.

***Assets and Liabilities Measured at Fair-Value***

On January 1, 2008, the Company adopted SFAS 157, which defines fair-value, establishes a framework for measuring fair-value, and expands disclosures about fair-value measurements. SFAS 157 applies to reported balances that are required or permitted to be measured at fair-value under existing accounting pronouncements; accordingly, the standard does not require any new fair-value measurements of reported balances.

**Table of Contents**

On January 1, 2008, the Company adopted SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities*, which permits companies to choose to measure certain financial instruments and other items at fair-value in order to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently. However, the Company has not elected to measure any additional financial instruments and other items at fair-value (other than those previously required under other GAAP rules or standards) under the provisions of this standard.

SFAS 157 emphasizes that fair-value is a market-based measurement, not an entity-specific measurement. Therefore, a fair-value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair-value measurements, SFAS 157 establishes a fair-value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair-value measurement is based on inputs from different levels of the fair-value hierarchy, the level in the fair-value hierarchy within which the entire fair-value measurement falls is based on the lowest level input that is significant to the fair-value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair-value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

The Company has used forward starting and interest rate swaps to manage its interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves. The fair-values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash receipts (or payments) and the discounted expected variable cash payments (or receipts). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. To comply with the provisions of SFAS 157, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty's nonperformance risk in the fair-value measurements. In adjusting the fair-value of its derivative contracts for the effect of nonperformance risk, the Company has considered the impact of netting and any applicable credit enhancements, such as collateral postings, thresholds, mutual puts, and guarantees.

Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair-value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by itself and its counterparties. However, as of June 30, 2009, the Company has determined that the impact of the credit valuation adjustments on the overall valuation of its derivative positions is not significant. As a result, the Company has determined that its derivative valuations in their entirety are classified in Level 2 of the fair-value hierarchy (see Note 9).

The valuation of the Company's investments in publicly-traded investments utilizes observable market-based inputs, based on the closing trading price of securities as of the balance sheet date. Although the Company has determined that the majority of the inputs used to value its investments fall within Level 1 of the fair-value hierarchy, discounts that may be applied to investments in private companies utilize Level 3 inputs. However, as of June 30, 2009, the Company has determined that the impact of the discounts on the overall valuation of its investments is not significant. As a result, the Company has determined that valuations of its investments in their entirety are classified in Level 1 of the fair-value hierarchy.



No other assets or liabilities are measured at fair-value on a recurring basis, or have been measured at fair-value on a non-recurring basis subsequent to initial recognition, in the accompanying consolidated balance sheets as of June 30, 2009.

**Table of Contents*****Derivative Instruments***

On January 1, 2009, the Company adopted SFAS No. 161, *Disclosures about Derivative Instruments and Hedging Activities, an amendment of FASB Statement No. 133* ( SFAS 161 ), which amends and expands the disclosure requirements of SFAS No. 133, *Accounting for Derivative Instruments and Hedging Activities* ( SFAS 133 ), with the intent to provide users of financial statements with an enhanced understanding of: (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect a company's financial position, financial performance, and cash flows. SFAS 161 requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about the fair-value of and gains and losses on derivative instruments, and disclosures about credit risk-related contingent features in derivative instruments.

The Company records all derivatives on the consolidated balance sheets at fair-value. In determining the fair-value of its derivatives, the Company considers the credit risk of its counterparties. These counterparties are generally larger financial institutions engaged in providing a variety of financial services. These institutions generally face similar risks regarding adverse changes in market and economic conditions, including, but not limited to, fluctuations in interest rates, exchange rates, equity and commodity prices and credit spreads. The current and pervasive disruptions in the financial markets have heightened the risks to these institutions. While management believes that its counterparties will meet their obligations under the derivative contracts, it is possible that defaults may occur.

The accounting for changes in the fair-value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. Derivatives designated and qualifying as a hedge of the exposure to changes in the fair-value of an asset, liability, or firm commitment attributable to a particular risk, such as interest rate risk, are considered fair-value hedges. Derivatives designated and qualifying as a hedge of the exposure to variability in expected future cash flows, or other types of forecasted transactions, are considered cash flow hedges. Derivatives may also be designated as hedges of the foreign currency exposure of a net investment in a foreign operation. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the recognition of the changes in the fair-value of the hedged asset or liability that are attributable to the hedged risk in a fair-value hedge or the earnings effect of the hedged forecasted transactions in a cash flow hedge. The Company may enter into derivative contracts that are intended to economically hedge certain of its risks, even though hedge accounting does not apply or the Company elects not to apply hedge accounting under SFAS 133.

For derivatives designated as cash flow hedges, the effective portion of changes in the fair-value of the derivative is initially reported in accumulated other comprehensive income (outside of earnings) and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings. If charges relating to the hedged transaction are being deferred pursuant to redevelopment or development activities, the effective portion of changes in the fair-value of the derivative are also deferred in other comprehensive income on the consolidated balance sheet, and are amortized to the income statement once the deferred charges from the hedged transaction begin again to affect earnings. The ineffective portion of changes in the fair-value of the derivative is recognized directly in earnings. The Company assesses the effectiveness of each hedging relationship by comparing the changes in cash flows of the derivative hedging instrument with the changes in cash flows of the designated hedged item or transaction.

The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity, and credit risk primarily by managing the amount, sources, and duration of its debt funding and the use of derivative financial instruments. Specifically, the Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known or expected cash amounts, the value of which are determined by interest rates. The Company's derivative financial instruments are used to manage differences in the amount, timing, and duration of the Company's known or expected cash receipts and its known or expected cash payments principally related to the Company's investments and borrowings.

The Company's objective in using derivatives is to add stability to interest expense and to manage its exposure to interest rate movements or other identified risks. To accomplish this objective, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying principal amount. During the three and six months ended June 30, 2009 and 2008, such derivatives were used to hedge the variable cash flows associated with existing variable-rate debt and future variability in the interest-related cash flows from forecasted issuances of debt (see Note 9). The Company formally documents the hedging relationships for all derivative instruments, has historically accounted for all of its interest rate swap agreements as cash flow hedges, and does not use derivatives for trading or speculative purposes.

**Table of Contents*****Management s Estimates***

Management has made a number of estimates and assumptions relating to the reporting of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reporting of revenues and expenses during the reporting period to prepare these consolidated financial statements in conformity with GAAP. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates under different assumptions or conditions.

***Segment Information***

The Company s properties share the following similar economic and operating characteristics: (1) they have similar forecasted returns (measured by capitalization rate at acquisition), (2) they are generally occupied almost exclusively by life science tenants that are public companies, government agencies or their subsidiaries, (3) they are generally located near areas of high life science concentrations with similar demographics and site characteristics, (4) the majority of properties are designed specifically for life science tenants that require infrastructure improvements not generally found in standard properties, and (5) the associated leases are primarily triple-net leases, generally with a fixed rental rate and scheduled annual escalations, that provide for a recovery of close to 100% of operating expenses. Consequently, the Company s properties qualify for aggregation into one reporting segment under the provisions of SFAS No. 131, *Disclosures about Segments of an Enterprise and Related Information*.

***Reclassifications and Adoption of New Accounting Pronouncements***

Certain prior year amounts have been reclassified to conform to the current year presentation. In addition, certain prior year amounts have been revised as a result of the adoption on January 1, 2009 of SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements* ( SFAS 160 ) (see Note 3), FASB Staff Position APB 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash Upon Conversion (Including Partial Cash Settlement)* ( FSP 14-1 ), an interpretation of APB Opinion No. 14, *Accounting for Convertible Debt and Debt Issued with Stock Purchase Warrants* (see Note 5), and FASB Staff Position EITF 03-6-1, *Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities* ( FSP 03-6-1 ) (see Note 6), which have been applied retroactively to prior periods.

**3. Equity**

During the six months ended June 30, 2009, the Company issued restricted stock awards to employees and to members of its board of directors totaling 353,600 and 10,000 shares of common stock, respectively (3,435 shares of common stock were surrendered to the Company and subsequently retired in lieu of cash payments for taxes due on the vesting of restricted stock and 15,611 shares of common stock were forfeited during that period), which are included in the total of common stock outstanding as of the period end (see Note 7).

On May 21, 2009, the Company completed the issuance of 16,754,854 shares of common stock, including the exercise of an over-allotment option of 754,854 shares, resulting in net proceeds of approximately \$166.9 million, after deducting the underwriters discount and commissions and offering expenses. The net proceeds to the Company were utilized to repay a portion of the outstanding indebtedness on its unsecured line of credit and for other general corporate and working capital purposes.

The Company maintains a Dividend Reinvestment Program and a Cash Option Purchase Plan (collectively, the DRIP Plan ) to provide existing stockholders of the Company with an opportunity to invest automatically the cash dividends paid upon shares of the Company s common stock held by them, as well as permit existing and prospective stockholders to make voluntary cash purchases. Participants may elect to reinvest a portion of, or the full amount of cash dividends paid, whereas optional cash purchases are normally limited to a maximum amount of \$10,000. In addition, the Company may elect to establish a discount ranging from 0% to 5% from the market price applicable to newly issued shares of common stock purchased directly from the Company. The Company may change the discount, initially set at 0%, at its discretion, but may not change the discount more frequently than once in any three-month period. Shares purchased under the DRIP Plan shall be, at the Company s option, purchased from either (1) authorized, but previously unissued shares of common stock, (2) shares of common stock purchased in the open market or privately negotiated transactions, or (3) a combination of both.

***Common Stock, Partnership Units and LTIP Units***

As of June 30, 2009, the Company had outstanding 98,118,639 shares of common stock and 2,607,164 and 566,540 partnership and LTIP units, respectively. A share of the Company's common stock and the partnership and LTIP units have essentially the same economic characteristics as they share equally in the total net income or loss and distributions of the Operating Partnership. The partnership units are further discussed below in this Note 3 and the LTIP units are discussed further below in this Note 3 and in Note 7.

**Table of Contents****7.375% Series A Cumulative Redeemable Preferred Stock**

As of June 30, 2009, the Company had outstanding 9,200,000 shares of 7.375% Series A cumulative redeemable preferred stock, or Series A preferred stock. Dividends are cumulative on the Series A preferred stock from the date of original issuance in the amount of \$1.84375 per share each year, which is equivalent to 7.375% of the \$25.00 liquidation preference per share. Dividends on the Series A preferred stock are payable quarterly in arrears on or about the 15th day of January, April, July and October of each year. Following a change in control, if the Series A preferred stock is not listed on the New York Stock Exchange, the American Stock Exchange or the Nasdaq Global Market, holders will be entitled to receive (when and as authorized by the board of directors and declared by the Company), cumulative cash dividends from, but excluding, the first date on which both the change of control and the delisting occurred at an increased rate of 8.375% per annum of the \$25.00 liquidation preference per share (equivalent to an annual rate of \$2.09375 per share) for as long as the Series A preferred stock is not listed. The Series A preferred stock does not have a stated maturity date and is not subject to any sinking fund or mandatory redemption provisions. Upon liquidation, dissolution or winding up, the Series A preferred stock will rank senior to the Company's common stock with respect to the payment of distributions and other amounts. The Company is not allowed to redeem the Series A preferred stock before January 18, 2012, except in limited circumstances to preserve its status as a REIT. On or after January 18, 2012, the Company may, at its option, redeem the Series A preferred stock, in whole or in part, at any time or from time to time, for cash at a redemption price of \$25.00 per share, plus all accrued and unpaid dividends on such Series A preferred stock up to, but excluding the redemption date. Holders of the Series A preferred stock generally have no voting rights except for limited voting rights if the Company fails to pay dividends for six or more quarterly periods (whether or not consecutive) and in certain other circumstances. The Series A preferred stock is not convertible into or exchangeable for any other property or securities of the Company.

**Dividends and Distributions**

The following table lists the dividends and distributions made by the Company and the Operating Partnership during the six months ended June 30, 2009:

| <b>Declaration Date</b> | <b>Securities Class</b>                     | <b>Amount Per Share/Unit</b> | <b>Period Covered</b>              | <b>Dividend and Distribution Payable Date</b> | <b>Dividend and Distribution Amount (in thousands)</b> |
|-------------------------|---|------------------------------|------------------------------------|---|--|
| March 16, 2009          | Common stock and partnership and LTIP units | \$ 0.33500                   | January 1, 2009 to March 31, 2009  | April 15, 2009                                | \$ 28,322  |
| March 16, 2009          | Series A preferred Stock                    | \$ 0.46094                   | January 16, 2009 to April 15, 2009 | April 15, 2009                                | \$ 4,240   |
| June 15, 2009           | Common stock and partnership and LTIP units | \$ 0.11000                   | April 1, 2009 to June 30, 2009     | July 15, 2009                                 | \$ 11,142  |
| June 15, 2009           | Series A preferred Stock                    | \$ 0.46094                   | April 16, 2009 to July 15, 2009    | July 15, 2009                                 | \$ 4,241   |

Total 2009 dividends and distributions declared through June 30, 2009:

|   |           |
|---|-----------|
| Common stock, partnership units, and LTIP units | \$ 39,464 |
| Series A preferred stock                        | 8,481     |
|   | \$ 47,945 |

**Noncontrolling Interests**

On January 1, 2009, the Company adopted SFAS 160, which clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial

statements. SFAS 160 also requires consolidated net income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest and requires disclosure, on the face of the consolidated statement of income, of the amounts of consolidated net income attributable to the parent and to the noncontrolling interest. In addition, SFAS 160 establishes a single method of accounting for changes in a parent's ownership interest in a subsidiary that does not result in deconsolidation and requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. As a result of the issuance of SFAS 160, the guidance in EITF Topic D-98, *Classification and Measurement of Redeemable Securities* ( D-98 ), was amended to include redeemable noncontrolling interests within its scope. If noncontrolling interests are determined to be redeemable, they are to be carried at their redemption value as of the balance sheet date and reported as temporary equity.

**Table of Contents**

Noncontrolling interests on the consolidated balance sheets relate primarily to the partnership and LTIP units in the Operating Partnership (collectively, the Units) that are not owned by the Company. In conjunction with the formation of the Company, certain persons and entities contributing interests in properties to the Operating Partnership received partnership units. In addition, certain employees of the Operating Partnership received LTIP units in connection with services rendered or to be rendered to the Operating Partnership. Limited partners who have been issued Units have the right to require the Operating Partnership to redeem part or all of their Units upon vesting of the Units, if applicable. The Company may elect to acquire those Units in exchange for shares of the Company's common stock on a one-for-one basis, subject to adjustment in the event of stock splits, stock dividends, issuance of stock rights, specified extraordinary distributions and similar events, or pay cash based upon the fair market value of an equivalent number of shares of the Company's common stock at the time of redemption. With respect to the noncontrolling interests in the Operating Partnership, D-98 requires that noncontrolling interests with the redemption provisions that permit the issuer to settle in either cash or common stock at the option of the issuer be further evaluated under EITF No. 00-19, *Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock* (EITF 00-19), paragraphs 12-32 to determine whether temporary or permanent equity classification on the balance sheet is appropriate. Since the Units comprising the noncontrolling interests contain such a provision, the Company evaluated this guidance and determined that the Units meet the requirements of EITF 00-19 to qualify for presentation as permanent equity.

SFAS 160 was required to be applied prospectively after adoption, with the exception of the presentation and disclosure requirements, which were applied retrospectively for all periods presented. As a result of the adoption of SFAS 160, the Company reclassified noncontrolling interests to permanent equity in the accompanying consolidated balance sheets. For the six months ended June 30, 2009, the Company recorded a decrease to the carrying value of noncontrolling interests of approximately \$636,000 (a corresponding increase was recorded to additional paid-in capital) to reflect the noncontrolling interests' proportionate share of equity at June 30, 2009. In periods subsequent to the adoption of SFAS 160, the Company will periodically evaluate individual noncontrolling interests for the ability to continue to recognize the noncontrolling interest as permanent equity in the consolidated balance sheets. Any noncontrolling interest that fails to qualify as permanent equity will be reclassified as temporary equity and adjusted to the greater of (a) the carrying amount, or (b) its redemption value as of the end of the period in which the determination is made.

The redemption value of the Units not owned by the Company at June 30, 2009 was approximately \$31.5 million based on the average closing price of the Company's common stock of \$9.91 per share for the ten consecutive trading days immediately preceding June 30, 2009.

The following table shows the vested ownership interests in the Operating Partnership:

|   | June 30, 2009                             |                        | December 31, 2008                         |                        |
|---|---|------------------------|---|------------------------|
|   | Partnership<br>Units<br>and LTIP<br>Units | Percentage of<br>Total | Partnership<br>Units<br>and LTIP<br>Units | Percentage of<br>Total |
| BioMed Realty Trust   | 97,293,984                                | 97.1%                  | 80,208,533                                | 96.3%                  |
| Noncontrolling interest consisting of:                              |   |                        |   |                        |
| Partnership and LTIP units held by<br>employees and related parties | 2,273,386                                 | 2.3%                   | 2,961,369                                 | 3.5%                   |
| Partnership and LTIP units held by third<br>parties(1)              | 665,802                                   | 0.6%                   | 122,192                                   | 0.2%                   |
| Total   | 100,233,172                               | 100.0%                 | 83,292,094                                | 100.0%                 |



- (1) Includes vested ownership interests held by a former employee, which are now classified as held by a third party.

A charge is recorded each period to the consolidated statements of income for the noncontrolling interests proportionate share of the Company's net income. An additional adjustment is made each period such that the carrying value of the noncontrolling interests equals the greater of (a) the noncontrolling interests' proportionate share of equity as of the period end, or (b) the redemption value of the noncontrolling interests as of the period end, if classified as temporary equity.

The accompanying consolidated financial statements include the results of investments in three variable interest entities in which the Company was considered to be the primary beneficiary under FIN 46R for some or all of the periods presented. As of June 30, 2009, the Company had an 87.5% interest in the limited liability company that owns the Ardenwood Venture property. This entity is consolidated in the accompanying consolidated financial statements. Equity interests in this limited liability company not owned by the Company are classified as a portion of the noncontrolling interests on the consolidated balance sheets as of June 30, 2009. Subject to certain conditions, the Company has the right to purchase the other member's interest or sell its own interest in the Ardenwood limited liability company. The estimated fair-value of this option is not material and the Company believes that it will have adequate resources to settle the option if exercised.

On June 2, 2008, pursuant to the exercise of a put option by the noncontrolling interest member, the Company completed the purchase of the remaining 30% interest in the limited liability company that owns the Waples Street property for consideration of approximately \$1.8 million, excluding closing costs. On October 14, 2008, the Company completed the purchase of the remaining 30% interest in the limited liability company that owns the 530 Fairview Avenue property for consideration of approximately \$2.6 million, excluding closing costs.

**Table of Contents****4. Mortgage Notes Payable**

A summary of the Company's outstanding consolidated mortgage notes payable was as follows (dollars in thousands):

|                                     | <b>Stated<br/>Fixed</b>  | <b>Effective</b>         | <b>Principal Balance</b> |                                  | <b>Maturity Date</b> |
|-------------------------------------|--------------------------|--------------------------|--------------------------|----------------------------------|----------------------|
|                                     | <b>Interest<br/>Rate</b> | <b>Interest<br/>Rate</b> | <b>June 30,<br/>2009</b> | <b>December<br/>31,<br/>2008</b> |                      |
| Ardentech Court                     | 7.25%                    | 5.06%                    | \$ 4,409                 | \$ 4,464                         | July 1, 2012         |
| Bayshore Boulevard                  | 4.55%                    | 4.55%                    | 14,709                   | 14,923                           | January 1, 2010      |
| Bridgeview Technology Park<br>I     | 8.07%                    | 5.04%                    | 11,315                   | 11,384                           | January 1, 2011      |
| Center for Life Science  <br>Boston | 7.75%                    | 7.75%                    | 350,000                  |                                  | June 30, 2014        |
| 500 Kendall Street (Kendall<br>D)   | 6.38%                    | 5.45%                    | 66,958                   | 67,810                           | December 1, 2018     |
| Lucent Drive                        | 5.50%                    | 5.50%                    | 5,237                    | 5,341                            | January 21, 2015     |
| Monte Villa Parkway                 | 4.55%                    | 4.55%                    | 8,954                    | 9,084                            | January 1, 2010      |
| 6828 Nancy Ridge Drive              | 7.15%                    | 5.38%                    | 6,645                    | 6,694                            | September 1, 2012    |
| Road to the Cure                    | 6.70%                    | 5.78%                    | 15,080                   | 15,200                           | January 31, 2014     |
| Science Center Drive                | 7.65%                    | 5.04%                    | 11,065                   | 11,148                           | July 1, 2011         |
| Shady Grove Road                    | 5.97%                    | 5.97%                    | 147,000                  | 147,000                          | September 1, 2016    |
| Sidney Street                       | 7.23%                    | 5.11%                    | 28,761                   | 29,184                           | June 1, 2012         |
| 9865 Towne Centre Drive             | 7.95%                    | 7.95%                    | 18,000                   |                                  | June 30, 2013        |
| 9885 Towne Centre Drive             | 4.55%                    | 4.55%                    | 20,452                   | 20,749                           | January 1, 2010      |
| 900 Uniqema Boulevard               | 8.61%                    | 5.61%                    | 1,276                    | 1,357                            | May 1, 2015          |
|                                     |                          |                          | 709,861                  | 344,338                          |                      |
| Unamortized premiums                |                          |                          | 7,903                    | 8,823                            |                      |
|                                     |                          |                          | \$ 717,764               | \$ 353,161                       |                      |

On June 19, 2009, the Company closed on an \$18.0 million mortgage loan, which is secured by the Company's 9865 Towne Centre Drive property in San Diego, California. The mortgage loan bears interest at a fixed-rate of 7.95% per annum and matures in June 2013.

On June 29, 2009, the Company closed on a \$350.0 million mortgage loan, which is secured by the Company's Center for Life Science | Boston property in Boston, Massachusetts. The mortgage loan bears interest at a fixed-rate of 7.75% per annum and matures in June 2014. The Company utilized the net proceeds from the new mortgage loan, along with borrowings from its unsecured line of credit, to repay the outstanding \$507.1 million secured construction loan, which was secured by the Center for Life Science | Boston property. The new loan includes a financial covenant relating to a minimum amount of net worth. Management believes that it was in compliance with this covenant as of June 30, 2009.

Premiums were recorded upon assumption of the mortgage notes payable at the time of acquisition to account for above-market interest rates. Amortization of these premiums is recorded as a reduction to interest expense over the remaining term of the respective note using the effective-interest method.

The Company intends to repay any principal and accrued interest due in the next twelve months through the use of cash from operations or borrowings from its unsecured line of credit.

**5. Credit Facilities, Exchangeable Senior Notes, and Other Debt Instruments*****Unsecured Line of Credit***

The Company's unsecured line of credit with KeyBank National Association ( KeyBank ) and other lenders has a borrowing capacity of \$600.0 million and a maturity date of August 1, 2011. The unsecured line of credit bears interest at a floating rate equal to, at the Company's option, either (1) reserve-adjusted LIBOR plus a spread which ranges from 100 to 155 basis points, depending on the Company's leverage, or (2) the higher of (a) the prime rate then in effect plus a spread which ranges from 0 to 25 basis points, or (b) the federal funds rate then in effect plus a spread which ranges from 50 to 75 basis points, in each case, depending on the Company's leverage. Subject to the administrative agent's reasonable discretion, the Company may increase the amount of the unsecured line of credit to \$1.0 billion upon satisfying certain conditions. In addition, the Company, at its sole discretion, may extend the maturity date of the unsecured line of credit to August 1, 2012 after satisfying certain conditions and paying an extension fee based on the then current facility commitment. The Company has deferred the loan costs associated with the subsequent amendments to the unsecured line of credit, which are being amortized to expense with the unamortized loan costs from the original debt facility over the remaining term. At June 30, 2009, the Company had \$292.4 million in outstanding borrowings on its unsecured line of credit, with a weighted average interest rate of 1.4% on the unhedged portion of the outstanding debt of approximately \$142.4 million.

**Table of Contents*****Secured Term Loan***

The Company's \$250.0 million secured term loan from KeyBank and other lenders, which is secured by the Company's interests in twelve of its properties, has a maturity date of August 1, 2012. The secured term loan bears interest at a floating rate equal to, at the Company's option, either (1) reserve-adjusted LIBOR plus 165 basis points or (2) the higher of (a) the prime rate then in effect plus 25 basis points or (b) the federal funds rate then in effect plus 75 basis points. The secured term loan is also secured by the Company's interest in any distributions from these properties, a pledge of the equity interests in a subsidiary owning one of these properties, and a pledge of the equity interests in a subsidiary owning an interest in another of these properties. At June 30, 2009, the Company had \$250.0 million in outstanding borrowings on its secured term loan, with an interest rate of 2.0% (excluding the effect of interest rate swaps).

The terms of the credit agreements for the unsecured line of credit and the secured term loan include certain restrictions and covenants, which limit, among other things, the payment of dividends and the incurrence of additional indebtedness and liens. The terms also require compliance with financial ratios relating to the minimum amounts of net worth, fixed charge coverage, unsecured debt service coverage, the maximum amount of secured, and secured recourse indebtedness, leverage ratio and certain investment limitations. The dividend restriction referred to above provides that, except to enable the Company to continue to qualify as a REIT for federal income tax purposes, the Company will not make distributions with respect to common stock or other equity interests in an aggregate amount for the preceding four fiscal quarters in excess of 95% of funds from operations, as defined, for such period, subject to other adjustments. Management believes that it was in compliance with the covenants as of June 30, 2009.

***Exchangeable Senior Notes, net***

On September 25, 2006, the Operating Partnership issued \$175.0 million aggregate principal amount of its 4.50% Exchangeable Senior Notes due 2026 (the Notes). The Notes are general senior unsecured obligations of the Operating Partnership and rank equally in right of payment with all other senior unsecured indebtedness of the Operating Partnership. Interest at a rate of 4.50% per annum is payable on April 1 and October 1 of each year, beginning on April 1, 2007, until the stated maturity date of October 1, 2026. The terms of the Notes are governed by an indenture, dated September 25, 2006, among the Operating Partnership, as issuer, the Company, as guarantor, and U.S. Bank National Association, as trustee. The Notes contain an exchange settlement feature, which provides that the Notes may, on or after September 1, 2026 or under certain other circumstances, be exchangeable for cash (up to the principal amount of the Notes) and, with respect to excess exchange value, into, at the Company's option, cash, shares of the Company's common stock or a combination of cash and shares of common stock at the then applicable exchange rate. The initial exchange rate was 26.4634 shares per \$1,000 principal amount of Notes, representing an exchange price of approximately \$37.79 per share. If certain designated events occur on or prior to October 6, 2011 and a holder elects to exchange Notes in connection with any such transaction, the Company will increase the exchange rate by a number of additional shares of common stock based on the date the transaction becomes effective and the price paid per share of common stock in the transaction, as set forth in the indenture governing the Notes. The exchange rate may also be adjusted under certain other circumstances, including the payment of cash dividends in excess of \$0.29 per share of common stock. The increase in the quarterly cash dividend to \$0.335 per share of common stock for 2008 resulted in an increase in the exchange rate to 26.8135 per \$1,000 principal amount of Notes, effective as of December 29, 2008, the Company's ex dividend date. The Operating Partnership may redeem the Notes, in whole or in part, at any time to preserve the Company's status as a REIT or at any time on or after October 6, 2011 for cash at 100% of the principal amount plus accrued and unpaid interest. The holders of the Notes have the right to require the Operating Partnership to repurchase the Notes, in whole or in part, for cash on each of October 1, 2011, October 1, 2016 and October 1, 2021, or upon the occurrence of a designated event, in each case for a repurchase price equal to 100% of the principal amount of the Notes plus accrued and unpaid interest. At June 30, 2009 and 2008, the Notes had a contractual interest rate of 4.5%, which resulted in interest expense for the three and six months ended June 30, 2009 of approximately \$1.2 million and \$2.7 million, respectively, and for the three and six months ended June 30, 2008 of approximately \$2.0 million and \$3.9 million, respectively.

On January 1, 2009, the Company adopted FSP 14-1, which requires the issuer of certain convertible debt instruments that may be settled in cash (or other assets) on conversion to separately account for the liability (debt) and equity

(conversion option) components of the instrument in a manner that reflects the issuer's nonconvertible debt borrowing rate. The equity component of the convertible debt is included in the additional paid-in capital section of stockholders equity and the value of the equity component is treated as original issue discount for purposes of accounting for the debt component of the debt security. The resulting debt discount will be accreted as additional interest expense over the non-cancelable term of the instrument. Retrospective application was required and has been reflected in all periods presented. The adoption of FSP 14-1 by the Company on January 1, 2009 resulted in a decrease to the gain on extinguishment of debt recognized in the fourth quarter of 2008 of approximately \$2.3 million (or approximately \$0.03 per diluted share) as a result of the retrospective application of the standard to earlier periods. In addition, adoption of FSP 14-1 resulted in an increase in the recognition of additional non-cash interest expense of approximately \$5.9 million during the period from the date of issuance of the Notes through December 2008, partially offset by the recognition of additional capitalized interest of approximately \$2.7 million. However, the adoption of FSP 14-1 did not change the previously reported earnings per share for the periods presented. As of June 30, 2009 and December 31, 2008, the carrying value of the equity component recognized in connection with the adoption of FSP 14-1 was approximately \$14.0 million.

**Table of Contents**

In March 2009, the Company completed the repurchase of approximately \$12.0 million face value of the Notes for approximately \$6.9 million. In April 2009, the Company completed an additional repurchase of approximately \$8.8 million face value of the Notes for approximately \$5.7 million. The repurchase of the Notes resulted in the recognition of a gain on extinguishment of debt of approximately \$2.6 million and \$7.0 million for the three and six months ended June 30, 2009, respectively (net of the write-off of approximately \$510,000 and \$1.2 million in deferred loan fees and debt discount for the three and six months ended June 30, 2009, respectively), which is reflected in the consolidated statements of income.

Exchangeable senior notes, net, consisted of the following (in thousands):

|                              | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008<br/>(Revised)</b> |
|------------------------------|--------------------------|--|
| Exchangeable senior notes    | \$ 107,420               | \$ 128,250                                 |
| Unamortized debt discount(1) | (4,343)                  | (6,207)                                    |
|                              | <b>\$ 103,077</b>        | <b>\$ 122,043</b>                          |

- (1) The unamortized debt discount will be amortized through October 1, 2011, the first date at which the holders of the Notes may require the Operating Partnership to repurchase the Notes. Amortization of the debt discount during the three and six months ended June 30, 2009 and 2008 resulted in an effective interest rate of 6.5% on the Notes and additional interest expense of

approximately  
\$453,000 and  
\$936,000,  
respectively,  
and \$683,000  
and  
\$1.3 million,  
respectively.

### ***Secured Construction Loan***

The Company's \$550.0 million secured construction loan from KeyBank, which was secured by the Center for Life Science | Boston property, was repaid in June 2009 from the proceeds received from the new mortgage loan secured by the property, along with borrowings from the Company's unsecured line of credit (see Note 4). In connection with the repayment of the secured construction loan, the Company wrote off approximately \$843,000 of deferred loan fees in the three months ended June 30, 2009, which are reflected in the consolidated statements of income as a reduction of the gain on extinguishment of debt recognized from the repurchase of the Notes (see above).

As of June 30, 2009, principal payments due for the Company's consolidated indebtedness (mortgage notes payable excluding the debt premium of \$7.9 million, unsecured line of credit, secured term loan and the Notes excluding the debt discount of \$4.3 million) were as follows (in thousands):

|               |              |
|---------------|--------------|
| 2009          | \$ 3,884     |
| 2010          | 50,842       |
| 2011          | 322,295      |
| 2012          | 295,383      |
| 2013          | 26,051       |
| Thereafter(1) | 661,230      |
|               | \$ 1,359,685 |

(1) Includes  
\$107.4 million  
in principal  
payments of the  
Notes based on  
a contractual  
maturity date of  
October 1,  
2026.

### **6. Earnings Per Share**

On January 1, 2009, the Company adopted FSP 03-6-1, which addresses whether instruments granted in share-based payment transactions are participating securities prior to vesting and, therefore, need to be included in earnings allocation in computing basic earnings per share under the two-class method. The Company has adjusted its calculation of basic and diluted earnings per share to conform to the guidance provided in FSP 03-6-1, which also required retrospective application for all periods presented. The change in calculating basic and diluted earnings per share pursuant to the adoption of FSP 03-6-1 did not have a material effect on the amounts previously reported for the periods presented (with the exception of the amount of weighted-average basic and diluted shares utilized in the calculation).





**Table of Contents**

The two-class method is an earnings allocation method for calculating earnings per share when a company's capital structure includes either two or more classes of common stock or common stock and participating securities. Basic earnings per share under the two-class method is calculated based on dividends declared on common shares and other participating securities (distributed earnings) and the rights of participating securities in any undistributed earnings, which represents net income remaining after deduction of dividends accruing during the period. The undistributed earnings are allocated to all outstanding common shares and participating securities based on the relative percentage of each security to the total number of outstanding participating securities. Basic earnings per share represents the summation of the distributed and undistributed earnings per share class divided by the total number of shares.

As of June 30, 2009, all of the Company's participating securities (including the Units) receive dividends/distributions at an equal dividend/distribution rate per share/unit. As a result, the portion of net income allocable to the weighted-average restricted stock outstanding for the three and six months ended June 30, 2009 and 2008 has been deducted from net income allocable to common stockholders to calculate basic earnings per share. The calculation of diluted earnings per share for the three and six months ended June 30, 2009 and 2008 includes the outstanding Units (both vested and unvested) and restricted stock in the weighted-average shares, as well as an increase to net income allocable to common stockholders for the noncontrolling interest charge recognized during the respective period. No shares were contingently issuable upon settlement of the excess exchange value pursuant to the exchange settlement feature of the Notes (originally issued in 2006 - see Note 5) as the weighted-average common stock prices of \$10.04 and \$25.91 for the three months ended June 30, 2009 and 2008, respectively, and \$9.79 and \$24.20 for the six months ended June 30, 2009 and 2008, respectively, did not exceed the current exchange price then in effect of \$37.79 per share at June 30, 2009 and \$37.29 per share at June 30, 2008, respectively. Therefore, potentially issuable shares resulting from settlement of the Notes were not included in the calculation of diluted weighted-average shares. No other shares were considered antidilutive for the three and six months ended June 30, 2009 and 2008.

Computations of basic and diluted earnings per share in accordance with SFAS No. 128, *Earnings per Share* and FSP 03-6-1 (in thousands, except share data) were as follows:

|  | <b>Three Months Ended<br/>June 30,</b> |                           | <b>Six Months Ended<br/>June 30,</b> |                           |
|--|--|---------------------------|--------------------------------------|---------------------------|
|  | <b>2009</b>                            | <b>2008<br/>(Revised)</b> | <b>2009</b>                          | <b>2008<br/>(Revised)</b> |
| <b>Basic earnings per share:</b>   |  |                           |                                      |                           |
| Net income available to common stockholders  | \$ 18,195                              | \$ 13,705                 | \$ 37,219                            | \$ 26,036                 |
| Less: net income allocable to unvested restricted stock  | (169)                                  | (42)                      | (361)                                | (86)                      |
| Less: distributions in excess of earnings attributable to unvested restricted stock            |  | (35)                      | (22)                                 | (74)                      |
| Net income attributable to common stockholders   | \$ 18,026                              | \$ 13,628                 | \$ 36,836                            | \$ 25,876                 |
| <b>Diluted earnings per share:</b>   |  |                           |                                      |                           |
| Net income available to common stockholders  | \$ 18,195                              | \$ 13,705                 | \$ 37,219                            | \$ 26,036                 |
| Plus: net income attributable to noncontrolling interests of operating partnership             | 658                                    | 619                       | 1,380                                | 1,209                     |
| Net income available to common stockholders and participating securities (including the Units) | \$ 18,853                              | \$ 14,324                 | \$ 38,599                            | \$ 27,245                 |
| <b>Weighted-average common shares outstanding:</b>   |  |                           |                                      |                           |
| Basic  | 88,503,295                             | 70,094,003                | 84,403,582                           | 67,722,258                |

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

Incremental shares from assumed  
conversion/vesting:

|                                      |            |            |            |            |
|--------------------------------------|------------|------------|------------|------------|
| Unvested restricted stock            | 832,233    | 215,066    | 829,115    | 225,262    |
| Operating partnership and LTIP units | 3,280,407  | 3,502,528  | 3,347,375  | 3,470,746  |
| Diluted                              | 92,615,935 | 73,811,597 | 88,580,072 | 71,418,266 |

**Basic and diluted earnings per share:**

|   |         |         |         |         |
|---|---------|---------|---------|---------|
| Net income per share available to common<br>stockholders, <i>basic and diluted:</i> | \$ 0.20 | \$ 0.19 | \$ 0.44 | \$ 0.38 |
|---|---------|---------|---------|---------|

**Table of Contents****7. Incentive Award Plan**

The Company has adopted the BioMed Realty Trust, Inc. and BioMed Realty, L.P. 2004 Incentive Award Plan (the Plan ). The Plan provides for grants to directors, employees and consultants of the Company and the Operating Partnership (and their respective subsidiaries) of stock options, restricted stock, LTIP units, stock appreciation rights, dividend equivalents and other incentive awards. The Company has reserved 5,340,000 shares of common stock for issuance pursuant to the Plan, subject to adjustments as set forth in the Plan. As of June 30, 2009, 3,251,325 shares of common stock or awards convertible into or exchangeable for common stock remained available for future issuance under the Plan. Each LTIP unit issued will count as one share of common stock for purposes of calculating the limit on shares that may be issued. Compensation cost for these incentive awards is measured based on the fair-value of the award on the grant date (fair-value is calculated based on the closing price of the Company's common stock on the date of grant) and is recognized as expense over the respective vesting period, which for restricted stock awards and LTIP units is generally two to five years. Fully vested incentive awards may be settled for either cash or stock depending on the Company's election and the type of award granted. Participants are entitled to cash dividends and may vote such awarded shares, but the sale or transfer of such shares is limited during the restricted or vesting period. Through June 30, 2009, the Company had only awarded restricted stock grants and LTIP units. The restricted stock grants may only be settled for stock whereas the LTIP units may be redeemed for either cash or common stock, at the Company's election.

LTIP units represent a profits interest in the Operating Partnership for services rendered or to be rendered by the LTIP unit holder in its capacity as a partner, or in anticipation of becoming a partner, in the Operating Partnership. Initially, LTIP units do not have full parity with common units of the Operating Partnership with respect to liquidating distributions, although LTIP unit holders receive the same quarterly per unit distributions as common units and may vote the LTIP units from the date of issuance. The LTIP units are subject to vesting requirements, which lapse over a specified period of time (generally three to five years from the date of issuance). In addition, the LTIP units are generally subject to a two-year lock-up period during which time the LTIP units may not be redeemed or sold by the LTIP unit holder. Upon the occurrence of specified events, LTIP units may over time achieve full parity with common units of the Operating Partnership for all purposes. Upon achieving full parity, and after the expiration of any vesting and lock-up periods, LTIP units may be redeemed for an equal number of the Company's common stock or cash, at the Company's election.

During the three months ended June 30, 2009 and 2008, the Company granted 10,000 shares of unvested restricted stock with an aggregate value of \$97,000, and 18,300 shares of unvested restricted stock and LTIP units with an aggregate value of \$471,000 under the Plan, respectively. For both the three months ended June 30, 2009 and 2008, a total of 10,000 shares of restricted stock vested, with fair-values of \$105,000 and \$272,000, respectively. During the six months ended June 30, 2009 and 2008, the Company granted 363,600 shares of unvested restricted stock with an aggregate value of \$4.0 million, and 217,415 shares of unvested restricted stock and LTIP units with an aggregate value of \$4.9 million under the Plan, respectively. For the six months ended June 30, 2009 and 2008, a total of 189,658 (3,435 shares of common stock, were surrendered to the Company and subsequently retired in lieu of cash payments for taxes due on the vesting of restricted stock) and 237,103 shares of restricted stock and LTIP units vested, with fair-values of \$2.0 million and \$5.5 million, respectively. For the three months ended June 30, 2009 and 2008, \$1.4 million and \$1.5 million of stock-based compensation expense was recognized in general and administrative expense and rental operations expense, respectively. In each of the six months ended June 30, 2009 and 2008, \$2.8 million of stock-based compensation expense was recognized in general and administrative expense and rental operations expense. As of June 30, 2009, total stock-based compensation expense related to unvested awards of \$13.2 million will be recognized in the future over a weighted-average period of 3.0 years.

A summary of the Company's unvested restricted stock and LTIP units is as follows:

| <b>Restricted Stock<br/>and<br/>LTIP Units</b> | <b>Weighted-<br/>Average Grant-<br/>Date Fair-Value</b> |
|--|---|
|--|---|

Edgar Filing: BioMed Realty Trust Inc - Form 10-Q

|                            |           |    |       |
|----------------------------|-----------|----|-------|
| Balance at January 1, 2009 | 900,841   | \$ | 18.92 |
| Granted                    | 353,600   |    | 11.03 |
| Vested                     | (179,658) |    | 27.04 |
| Balance at March 31, 2009  | 1,074,783 |    | 14.97 |
| Granted                    | 10,000    |    | 9.65  |
| Forfeited                  | (15,611)  |    | 12.50 |
| Vested                     | (10,000)  |    | 26.69 |
| Balance at June 30, 2009   | 1,059,172 |    | 14.84 |

|                            | <b>Restricted Stock<br/>and<br/>LTIP Units</b> |    | <b>Weighted-<br/>Average Grant-<br/>Date Fair-Value</b> |
|----------------------------|--|----|---|
| Balance at January 1, 2008 | 664,318  | \$ | 27.81   |
| Granted                    | 199,115  |    | 22.29   |
| Vested                     | (227,103)                                      |    | 23.93   |
| Balance at March 31, 2008  | 636,330  |    | 26.37   |
| Granted                    | 18,300   |    | 25.75   |
| Forfeited                  | (12,327)                                       |    | 25.93   |
| Vested                     | (10,000)                                       |    | 26.33   |
| Balance at June 30, 2008   | 632,303  |    | 26.33   |

**Table of Contents****8. Investment in Unconsolidated Partnerships**

The accompanying consolidated financial statements include investments in two limited liability companies with Prudential Real Estate Investors ( PREI ), which were formed in the second quarter of 2007, and in 10165 McKellar Court, L.P. ( McKellar Court ), a limited partnership with Quidel Corporation, the tenant which occupies the McKellar Court property. One of the PREI limited liability companies, PREI II LLC, is a variable interest entity as defined in FIN 46R; however, the Company is not the primary beneficiary. PREI will bear the majority of any losses. The other PREI limited liability company, PREI I LLC, does not qualify as a variable interest entity as defined in FIN 46R. In addition, consolidation under EITF 04-5 is not required as the Company does not control the limited liability companies. The McKellar Court partnership is a variable interest entity as defined in FIN 46R; however, the Company is not the primary beneficiary. The limited partner at McKellar Court is the only tenant in the property and will bear the majority of any losses. As it does not control the limited liability companies or the partnership, the Company accounts for them under the equity method of accounting. Significant accounting policies used by the unconsolidated partnerships that own these properties are similar to those used by the Company. General information on the PREI limited liability companies and the McKellar Court partnership (each referred to in this footnote individually as a partnership and collectively as the partnerships ) as of June 30, 2009 was as follows:

| <b>Name</b>       | <b>Partner</b>     | <b>Company s<br/>Ownership<br/>Interest</b> | <b>Company s<br/>Economic<br/>Interest</b> | <b>Date Acquired</b> |
|-------------------|--------------------|---|--|----------------------|
| PREI I LLC(1)     | PREI               | 20%   | 20%  | April 4, 2007        |
| PREI II LLC(2)    | PREI               | 20%   | 20%  | April 4, 2007        |
| McKellar Court(3) | Quidel Corporation | 21%   | 21%(4)                                     | September 30, 2004   |

(1) PREI I LLC acquired a portfolio of properties in Cambridge, Massachusetts comprised of a stabilized laboratory/office building totaling 184,405 square feet located at 320 Bent Street, a partially leased laboratory/office building totaling 417,290 square feet located at 301 Binney Street, a 37-unit apartment building, an operating garage facility on Rogers Street, an

operating below grade garage facility at Kendall Square, and a building currently under construction at 650 East Kendall Street that the Company believes can support up to 280,000 rentable square feet of laboratory and office space. The 650 East Kendall Street site will also include a below grade parking facility.

Each of the PREI operating agreements includes a put/call option whereby either member can cause the limited liability company to sell certain properties in which it holds leasehold interests to the Company at any time after the fifth anniversary and before the seventh anniversary of the acquisition date. However, the put/call option may be terminated prior to exercise under certain circumstances. The put/call

option purchase price is based on a predetermined return on capital invested by PREI. If the put/call option is exercised, the Company believes that it would have adequate resources to fund the purchase price and also has the option to fund a portion of the purchase price through the issuance of Company common stock.

The PREI limited liability companies jointly entered into a secured acquisition and interim loan facility with KeyBank and utilized approximately \$427.0 million of that facility to fund a portion of the purchase price for the properties acquired in April 2007. The remaining funds available were utilized to fund construction costs at certain properties under development. Pursuant to the loan facility, the

Company executed guaranty agreements in which it guaranteed the full completion of the construction and any tenant improvements at the 301 Binney Street property if PREI I LLC is unable or unwilling to complete the project. On February 11, 2009, the PREI joint ventures jointly refinanced the outstanding balance of the secured acquisition and interim loan facility, or approximately \$364.1 million, with the proceeds of a new loan totaling \$203.3 million and members capital contributions funding the balance due. The new loan bears interest at a rate equal to, at the option of the PREI joint ventures, either (1) reserve adjusted LIBOR plus 350 basis points or (2) the higher of (a) the



prime rate then in effect, (b) the federal funds rate then in effect plus 50 basis points or (c) one-month LIBOR plus 450 basis points, and requires interest only monthly payments until the maturity date, February 10, 2011. In addition, the PREI joint ventures may extend the maturity date of the secured acquisition and interim loan facility to February 10, 2012 after satisfying certain conditions and paying an extension fee based on the then current facility commitment. On March 11, 2009, the PREI joint ventures jointly entered into an interest rate cap agreement, which is intended to have the effect of hedging variability in future interest payments on the \$203.3 million secured acquisition and interim loan facility above a strike rate of

2.5% (excluding the applicable credit spread) through February 10, 2011. At June 30, 2009, there were \$203.3 million in outstanding borrowings on the secured acquisition and interim loan facility, with a contractual interest rate of 3.8% (including the applicable credit spread).

**Table of Contents**

- (2) PREI II LLC acquired a portfolio of properties comprised of a development parcel in Houston, Texas; a laboratory/office building totaling 259,706 rentable square feet and fee simple and leasehold interests in surrounding land parcels located at the Science Park at Yale in New Haven, Connecticut; and 25,000 rentable square feet of retail space and additional pad sites for future development in Cambridge, Massachusetts. On August 2, 2007, PREI II LLC completed the disposition of the 25,000 square feet of retail and additional pad sites in Cambridge, Massachusetts. The total sale price included approximately \$4.0 million contingently payable in June 2012

pursuant to a put/call option, exercisable on the earlier of the extinguishment or expiration of development restrictions placed on a portion of the development rights included in the disposition.

On September 28, 2007, PREI II LLC completed the disposition of the laboratory/office building and the fee simple and leasehold interests in surrounding land parcels in New Haven, Connecticut. On December 28, 2007, PREI II LLC completed the disposition of the development parcel in Houston, Texas. None of the sales resulted in the recognition of a material gain or loss. The Company's remaining investment in PREI II LLC (maximum exposure to losses) was approximately \$818,000 at June 30, 2009.

(3) The McKellar Court partnership holds a property comprised of a two-story laboratory/office building totaling 72,863 rentable square feet located in San Diego, California. The Company's investment in the McKellar Court partnership (maximum exposure to losses) was approximately \$2.4 million at June 30, 2009.

(4) The Company's economic interest in the McKellar partnership entitles it to 75% of the gains upon a sale of the property and 21% of the operating cash flows.

The Company acts as the operating member or partner, as applicable, and day-to-day manager for these partnerships. The Company is entitled to receive fees for providing construction and development services (as applicable) and management services to the PREI limited liability companies. The Company earned approximately \$702,000 and \$1.4 million in fees for the three and six months ended June 30, 2009, respectively, and \$836,000 and \$1.3 million in fees for the three and six months ended June 30, 2008, respectively, for services provided to the PREI limited liability companies, which are reflected in tenant recoveries and other income in the consolidated statements of income.

The condensed combined balance sheets for all of the Company's unconsolidated partnerships were as follows (in thousands):

|   | <b>June 30,<br/>2009</b> | <b>December 31,<br/>2008</b> |
|---|--------------------------|------------------------------|
| <b>Assets:</b>  |                          |                              |
| Investments in real estate, net                       | \$ 607,806               | \$ 592,169                   |
| Cash and cash equivalents (including restricted cash) | 5,473                    | 6,757                        |
| Intangible assets, net                                | 13,962                   | 15,126                       |
| Other assets  | 19,174                   | 16,373                       |

|   |            |            |
|---|------------|------------|
| Total assets  | \$ 646,415 | \$ 630,425 |
| <b>Liabilities and equity:</b>                          |            |            |
| Mortgage notes payable                                  | \$ 381,701 | \$ 517,938 |
| Other liabilities                                       | 21,346     | 24,844     |
| Members' equity   | 243,368    | 87,643     |
| Total liabilities and equity                            | \$ 646,415 | \$ 630,425 |
| Company's net investment in unconsolidated partnerships | \$ 49,243  | \$ 18,173  |

On February 13, 2008, a wholly owned subsidiary of PREI I LLC entered into a secured construction loan facility with certain lenders to provide borrowings of up to approximately \$245.0 million, with a maturity date of August 13, 2010, in connection with the construction of 650 East Kendall Street, a life sciences building located in Cambridge, Massachusetts. Proceeds from the secured construction loan were used in part to repay a portion of the secured acquisition and interim loan facility held by the PREI limited liability companies and are being used to fund the balance of the anticipated cost to complete construction of the project. In February 2008, the subsidiary entered into an interest rate swap agreement, which was intended to have the effect of initially fixing the interest rate on up to \$163.0 million of the secured construction loan facility at a weighted average rate of 4.4% through August 2010. The swap agreement had an original notional amount of \$84.0 million based on the initial borrowing on the secured construction loan facility, which increases on a monthly basis at predetermined amounts as additional borrowings are made. At June 30, 2009, there were \$168.2 million in outstanding borrowings on the secured construction loan facility, with a contractual interest rate of 1.8%.

During the six months ended June 30, 2009, the Company provided approximately \$32.4 million in additional funding to the PREI joint ventures pursuant to capital calls, primarily related to the refinancing of the secured acquisition and interim loan facility.

**Table of Contents**

The condensed combined statements of income for the unconsolidated partnerships were as follows (in thousands):

|  | <b>Three Months Ended</b> |             | <b>Six Months Ended</b> |             |
|--|---------------------------|-------------|-------------------------|-------------|
|  | <b>June 30,</b>           |             | <b>June 30,</b>         |             |
|  | <b>2009</b>               | <b>2008</b> | <b>2009</b>             | <b>2008</b> |
| Total revenues   | \$ 7,600                  | \$ 7,440    | \$ 15,328               | \$ 14,876   |
| Rental operations expense  | 2,269                     | 1,500       | 4,876                   | 3,129       |
| Real estate taxes  | 2,121                     | 1,828       | 4,242                   | 3,553       |
| Depreciation and amortization  | 3,304                     | 2,247       | 6,608                   | 4,495       |
| Interest expense, net of interest income                             | 2,523                     | 2,090       | 4,613                   | 4,695       |
| Total expenses   | 10,217                    | 7,665       | 20,339                  | 15,872      |
| Net loss   | \$ (2,617)                | \$ (225)    | \$ (5,011)              | \$ (996)    |
| Company's equity in (loss)/net income of unconsolidated partnerships | \$ (465)                  | \$ 43       | \$ (766)                | \$ (130)    |

**9. Derivatives and Other Financial Instruments**

As of June 30, 2009, the Company had three interest rate swaps with an aggregate notional amount of \$400.0 million under which at each monthly settlement date the Company either (1) receives the difference between a fixed interest rate (the Strike Rate) and one-month LIBOR if the Strike Rate is less than LIBOR or (2) pays such difference if the Strike Rate is greater than LIBOR. One interest rate swap with a notional amount of \$250.0 million hedges the Company's secured term loan. Each of the remaining two interest rate swaps hedges the first interest payments, due on the date that is on or closest after each swap's settlement date, associated with the amount of LIBOR-based debt equal to each swap's notional amount. One of these interest rate swaps has a notional amount of \$35.0 million (interest rate of 5.8%, including the applicable credit spread) and is currently intended to hedge interest payments associated with the Company's unsecured line of credit. The remaining interest rate swap has a notional amount of \$115.0 million (interest rate of 5.8%, including the applicable credit spread) and is also currently intended to hedge interest payments associated with the Company's unsecured line of credit. No initial investment was made to enter into the interest rate swap agreements.

As of June 30, 2009, the Company had unrealized losses of approximately \$66.9 million deferred in other comprehensive income related to forward starting swaps, which were settled with the corresponding counterparties in April 2009 for approximately \$77.6 million. The forward starting swaps were entered into to mitigate the Company's exposure to the variability in expected future cash flows attributable to changes in future interest rates associated with a forecasted issuance of at least \$368.0 million in fixed-rate debt, with interest payments for a minimum of ten years. In June 2009 the Company closed on \$368.0 million in fixed-rate mortgage loans secured by its 9865 Towne Centre Drive and Center for Life Science | Boston properties (see Note 4). The unrealized losses of \$66.9 million will be amortized as additional interest expense over ten years.

The following is a summary of the terms of the interest rate swaps and the forward starting swaps and their fair-values, which are included in derivative instruments (liability account) on the accompanying consolidated balance sheets (in thousands):

| <b>Notional Amount</b> | <b>Effective Date</b> | <b>Expiration Date</b> | <b>Fair-Value(1)</b> |                          |
|------------------------|-----------------------|------------------------|----------------------|--------------------------|
|                        |                       |                        | <b>June 30, 2009</b> | <b>December 31, 2008</b> |

|                              |            | <b>Strike<br/>Rate</b> |                   |                   |             |              |
|------------------------------|------------|------------------------|-------------------|-------------------|-------------|--------------|
|                              | \$ 250,000 | 4.157%                 | June 1, 2005      | June 1, 2010      | \$ (8,015)  | \$ (11,011)  |
|                              | 115,000    | 4.673%                 | October 1, 2007   | August 1, 2011    | (7,569)     | (9,349)      |
|                              | 35,000     | 4.700%                 | October 10, 2007  | August 1, 2011    | (2,326)     | (2,858)      |
| Interest rate swaps          | 400,000    |                        |                   |                   | (17,910)    | (23,218)     |
|                              | 150,000    | 5.162%                 | December 30, 2008 | December 30, 2018 |             | (34,307)     |
|                              | 50,000     | 5.167%                 | December 30, 2008 | December 30, 2018 |             | (11,449)     |
|                              | 100,000    | 5.167%                 | December 30, 2008 | December 30, 2018 |             | (22,942)     |
|                              | 150,000    | 5.152%                 | December 30, 2008 | December 30, 2018 |             | (34,175)     |
| Forward starting swaps (2)   | \$ 450,000 |                        |                   |                   | \$          | \$ (102,873) |
| Total derivative instruments | \$ 850,000 |                        |                   |                   | \$ (17,910) | \$ (126,091) |

(1) Fair-value of derivative instruments does not include any related accrued interest payable, which is included in accrued expenses on the accompanying consolidated balance sheets.

(2) One of the forward starting swaps was settled with the related counterparty in February 2009, resulting in payment by the Company of approximately \$8.9 million. The other three forward starting swaps, with an aggregate



notional value  
of  
\$400.0 million,  
were settled  
during the three  
months ended  
June 30, 2009  
for  
approximately  
\$77.6 million.

For derivatives designated as cash flow hedges, the effective portion of changes in the fair-value of the derivative is initially reported in accumulated other comprehensive income (outside of earnings) and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings. During the three and six months ended June 30, 2009 and 2008, such derivatives were used to hedge the variable cash flows associated with the Company's unsecured line of credit, secured term loan, secured construction loan, and the forecasted issuance of fixed-rate debt. The ineffective portion of the change in fair-value of the derivatives is recognized directly in earnings. During the three and six months ended June 30, 2009, the Company recorded a gain on derivative instruments of \$360,000 and \$303,000 as a result of hedge ineffectiveness and changes in the fair-value of derivative instruments, attributable to mismatches in the maturity date and the interest rate reset dates between the interest rate swap and corresponding debt, and changes in the fair-value of derivatives no longer considered highly effective. An immaterial amount of hedge ineffectiveness was recognized for the three and six months ended June 30, 2008.

**Table of Contents**

Amounts reported in accumulated other comprehensive income related to derivatives will be reclassified to interest expense as interest payments are made on the Company's variable-rate debt. During the next twelve months, the Company estimates that an additional \$21.4 million will be reclassified from other accumulated comprehensive income as an increase to interest expense. In addition, for the three and six months ended June 30, 2009, approximately \$754,000 and \$1.7 million of settlement payments, respectively, relating to our interest rate swaps have been deferred in accumulated other comprehensive income related to the Company's Pacific Research Center and Landmark at Eastview properties, and other properties currently under development or redevelopment.

The following is a summary of the amount of gain/(loss) recognized in accumulated other comprehensive income related to the derivative instruments for the three and six months ended June 30, 2009 and 2008:

|  | <b>Three Months Ended<br/>June 30,</b> |                  | <b>Six Months Ended<br/>June 30,</b> |                   |
|--|--|------------------|--------------------------------------|-------------------|
|  | <b>2009</b>                            | <b>2008</b>      | <b>2009</b>                          | <b>2008</b>       |
| <b>Amount of gain/(loss) recognized in other comprehensive income (effective portion):</b> |  |                  |                                      |                   |
| Cash flow hedges   |  |                  |                                      |                   |
| Interest rate swaps  | \$ 3,368                               | \$ 13,310        | \$ 5,355                             | \$ (1,011)        |
| Forward starting swaps   | 5,303                                  | 17,256           | 11,782                               | (491)             |
| Total cash flow hedges   | 8,671                                  | 30,566           | 17,137                               | (1,502)           |
| Ineffective interest rate swaps(1)   |  |                  | 4,321                                |                   |
| <b>Total interest rate swaps</b>   | <b>\$ 8,671</b>                        | <b>\$ 30,566</b> | <b>\$ 21,458</b>                     | <b>\$ (1,502)</b> |

(1) Amount represents the reclassification of unrealized losses from other comprehensive income to earnings during the three months ended March, 31, 2009 relating to a previously effective forward starting swap as a result of the reduction in the notional amount of forecasted debt.

The following is a summary of the amount of loss reclassified from accumulated other comprehensive income to interest expense related to the derivative instruments for the three and six months ended June 30, 2009 and 2008:

|   | <b>Three Months Ended</b> |                   | <b>Six Months Ended</b> |                   |
|---|---------------------------|-------------------|-------------------------|-------------------|
|   | <b>June 30,</b>           |                   | <b>June 30,</b>         |                   |
|   | <b>2009</b>               | <b>2008</b>       | <b>2009</b>             | <b>2008</b>       |
| <b>Amount of loss reclassified from other comprehensive income to income (effective portion):</b> |                           |                   |                         |                   |
| Cash flow hedges  |                           |                   |                         |                   |
| Interest rate swaps   | \$ (4,019)                | \$ (2,003)        | \$ (7,924)              | \$ (2,801)        |
| Forward starting swaps  |                           |                   |                         |                   |
| <b>Total interest rate swaps</b>  | <b>\$ (4,019)</b>         | <b>\$ (2,003)</b> | <b>\$ (7,924)</b>       | <b>\$ (2,801)</b> |

The following is a summary of the amount of gain/(loss) recognized in income as a loss on derivative instruments related to the ineffective portion of the derivative instruments for the three and six months ended June 30, 2009 and 2008:

|   | <b>Three Months Ended</b> |             | <b>Six Months Ended</b> |             |
|---|---------------------------|-------------|-------------------------|-------------|
|   | <b>June 30,</b>           |             | <b>June 30,</b>         |             |
|   | <b>2009</b>               | <b>2008</b> | <b>2009</b>             | <b>2008</b> |
| <b>Amount of gain/(loss) recognized in income (ineffective portion and amount excluded from effectiveness testing):</b> |                           |             |                         |             |
| Cash flow hedges  |                           |             |                         |             |
| Interest rate swaps   | \$ (1)                    | \$          | \$ (11)                 | \$          |
| Forward starting swaps  | (124)                     |             | (477)                   |             |
| Total cash flow hedges  | (125)                     |             | (488)                   |             |
| Ineffective interest rate swaps   | 485                       |             | 791                     |             |
| <b>Total interest rate swaps</b>  | <b>\$ 360</b>             | <b>\$</b>   | <b>\$ 303</b>           | <b>\$</b>   |

**Table of Contents****10. Fair-Value of Financial Instruments**

SFAS No. 107, *Disclosure about Fair-value of Financial Instruments*, requires the Company to disclose fair-value information about all financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate fair-value. The Company's disclosures of estimated fair-value of financial instruments at June 30, 2009 and December 31, 2008, were determined using available market information and appropriate valuation methods. Considerable judgment is necessary to interpret market data and develop estimated fair-value. The use of different market assumptions or estimation methods may have a material effect on the estimated fair-value amounts.

The carrying amounts for cash and cash equivalents, restricted cash, accounts receivable, security deposits, accounts payable, accrued expenses and other liabilities approximate fair-value due to the short-term nature of these instruments.

The Company utilizes quoted market prices to estimate the fair-value of its fixed-rate and variable-rate debt, when available. If quoted market prices are not available, the Company calculates the fair-value of its mortgage notes payable and other fixed-rate debt based on a currently available market rate assuming the loans are outstanding through maturity and considering the collateral. In determining the current market rate for fixed-rate debt, a market spread is added to the quoted yields on federal government treasury securities with similar terms to debt. In determining the current market rate for variable-rate debt, a market spread is added to the current effective interest rate. In accordance with SFAS 133, the carrying value of interest rate swaps, as well as the underlying hedged liability, if applicable, are reflected at their fair-value (see the Assets and Liabilities Measured at Fair-Value section under Note 2). The Company relies on quotations from a third party to determine these fair-values.

At June 30, 2009 and December 31, 2008, the aggregate fair-value and the carrying value of the Company's consolidated mortgage notes payable, unsecured line of credit, secured construction loan, Notes, secured term loan, derivative instruments and investments were as follows (in thousands):

|                           | June 30, 2009 |                | December 31, 2008 |                          |
|---------------------------|---------------|----------------|-------------------|--------------------------|
|                           | Fair-Value    | Carrying Value | Fair-Value        | Carrying Value (Revised) |
| Mortgage notes payable(1) | \$ 683,124    | \$ 717,764     | \$ 373,572        | \$ 353,161               |
| Unsecured line of credit  | 277,690       | 292,404        | 104,507           | 108,767                  |
| Secured construction loan |               |                | 500,162           | 507,128                  |
| Notes(2)                  | 91,844        | 103,077        | 60,278            | 122,043                  |
| Secured term loan         | 231,841       | 250,000        | 240,667           | 250,000                  |
| Derivative instruments(3) | (17,910)      | (17,910)       | (126,091)         | (126,091)                |
| Investments(4)            | 2,360         | 2,360          |                   |                          |

(1) Carrying value includes \$7.9 million and \$8.8 million of debt premium as of June 30, 2009 and December 31, 2008, respectively.

(2) Carrying value includes

\$4.3 million and \$6.2 million of debt discount as of June 30, 2009 and December 31, 2008, respectively.

- (3) The Company's derivative instruments are reflected as liabilities on the accompanying consolidated balance sheets (see Note 9).
- (4) The Company's investments are included in other assets on the accompanying consolidated balance sheets (see Investments section in Note 2).

#### **11. New Accounting Standards**

In May 2009, the FASB issued SFAS No. 165, *Subsequent Events* ( SFAS 165 ), which sets forth principles and requirements for subsequent events, specifically (1) the period during which management should evaluate events or transactions that may occur for potential recognition and disclosure, (2) the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date, and (3) the disclosures that an entity should make about events and transactions occurring after the balance sheet date. SFAS 165 is effective for interim reporting periods ending after June 15, 2009. The Company has adopted SFAS 165, which did not have a material impact on its consolidated financial statements.

**Table of Contents**

In June 2009, the FASB issued SFAS No. 166, *Accounting for Transfers of Financial Assets, an amendment of FASB Statement No. 140* ( SFAS 166 ), which was issued to improve the relevance, representational faithfulness, and comparability of the information that a reporting entity provides in its financial statements about (1) a transfer of its financial assets, (2) the effects of such a transfer on its financial position, financial performance, and cash flows, and (3) a reporting entity's continuing involvement, if any, in the transferred financial assets. SFAS 166 is effective for annual reporting periods beginning after November 15, 2009, for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter, with early adoption prohibited. The Company is currently evaluating the potential impact of the adoption of SFAS 166, but does not believe that it will have a material impact on its consolidated financial statements.

In June 2009, the FASB issued SFAS No. 167, *Amendments to FASB Interpretation No. 46(R)* ( SFAS 167 ), which amended certain requirements of FIN 46R to improve financial reporting disclosure by companies involved with variable interest entities and to provide more relevant and reliable information to users of financial statements. SFAS 167 is effective for annual reporting periods beginning after November 15, 2009, for interim periods within that first annual reporting period, and for interim and annual reporting periods thereafter, with early adoption prohibited. The Company is currently evaluating the potential impact of the adoption of SFAS 167 on its unconsolidated partnerships.

In June 2009, the FASB issued SFAS No. 168, *The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles, a replacement of FASB Statement No. 162* ( SFAS 168 ), which will become the source of authoritative U.S. GAAP recognized by the FASB to be applied to nongovernmental entities. On its effective date, SFAS 168 will supersede all then-existing non-SEC accounting and reporting standards. SFAS 168 is effective for financial statements issued for interim and annual periods ending after September 15, 2009. The Company is currently evaluating the potential impact of the adoption of SFAS 167, but does not believe that it will have a material impact on its consolidated financial statements.

**Table of Contents****ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

As used herein, the terms we, us, our or the Company refer to BioMed Realty Trust, Inc., a Maryland corporation, any of our subsidiaries.

The following discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this report. We make statements in this report that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, statements pertaining to our capital resources, portfolio performance and results of operations contain forward-looking statements. Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise, and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). You can identify forward-looking statements by the use of forward-looking terminology such as believes, expects, may, will, should, seeks, approximately, intends, plans, or the negative of these words and phrases or similar words or phrases. You can also identify forward-looking statements by discussions of strategy, plans or intentions. The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: adverse economic or real estate developments in the life science industry or in our target markets, including the ability of our tenants to obtain funding to run their businesses; our failure to obtain necessary outside financing on favorable terms or at all, including the continued availability of our unsecured line of credit; general economic conditions, including downturns in the national and local economies; volatility in financial and securities markets; defaults on or non-renewal of leases by tenants; our inability to compete effectively; increased interest rates and operating costs; our inability to successfully complete real estate acquisitions, developments and dispositions; risks and uncertainties affecting property development and construction; our failure to successfully operate acquired properties and operations; our failure to maintain our status as a REIT; government approvals, actions and initiatives, including the need for compliance with environmental requirements; and changes in real estate, zoning and other laws and increases in real property tax rates. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The risks included here are not exhaustive, and additional factors could adversely affect our business and financial performance, including factors and risks included in other sections of this report. In addition, we discussed a number of material risks in our annual report on Form 10-K for the year ended December 31, 2008. Those risks continue to be relevant to our performance and financial condition. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on our company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

**Overview**

We operate as a REIT focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. Our tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. Our properties are generally located in markets with well-established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey.

At June 30, 2009, our portfolio consisted of 69 properties, representing 114 buildings with an aggregate of approximately 10.5 million rentable square feet.

**Table of Contents**

The following reflects the classification of our properties between stabilized properties (operating properties in which more than 90% of the rentable square footage is under lease), lease up properties (operating properties in which less than 90% of the rentable square footage is under lease), redevelopment properties (properties that are currently being prepared for their intended use), construction in progress (properties that are currently under development through ground up construction), and land parcels (representing management's estimates of rentable square footage if development of these properties was undertaken) at June 30, 2009:

|                           | Consolidated Portfolio |                      |  | Unconsolidated Partnership Portfolio |                      |  | Total Portfolio |                      |  |
|---------------------------|------------------------|----------------------|--|--------------------------------------|----------------------|--|-----------------|----------------------|--|
|                           | Properties             | Rentable Square Feet | Percent of Rentable Square Feet Leased | Properties                           | Rentable Square Feet | Percent of Rentable Square Feet Leased | Properties      | Rentable Square Feet | Percent of Rentable Square Feet Leased |
| Stabilized properties     | 41                     | 5,830,252            | 98.5%                                  | 4                                    | 257,268              | 100.0%                                 | 45              | 6,087,520            | 98.5%                                  |
| Lease up properties       | 19                     | 3,214,843            | 42.6%                                  | 2                                    | 417,290              | 27.3%                                  | 21              | 3,632,133            | 40.8%                                  |
| Total operating portfolio | 60                     | 9,045,095            | 78.6%                                  | 6                                    | 674,558              | 55.1%                                  | 66              | 9,719,653            | 77.0%                                  |
| Redevelopment properties  | 1                      | 154,341              | 0.0%                                   |                                      |                      | n/a                                    | 1               | 154,341              | 0.0%                                   |
| Construction in progress  | 1                      | 360,520              | 63.7%                                  | 1                                    | 280,000              |  | 2               | 640,520              | 35.9%                                  |
| Total portfolio           | 62                     | 9,559,956            | 76.8%                                  | 7                                    | 954,558              | 38.9%                                  | 69              | 10,514,514           | 73.3%                                  |
| Land parcels              | n/a                    | 1,352,000            | n/a                                    |                                      |                      | n/a                                    | n/a             | 1,352,000            | n/a                                    |
| Total proforma portfolio  | 62                     | 10,911,956           | n/a                                    | 7                                    | 954,558              | n/a                                    | 69              | 11,866,514           | n/a                                    |

**Factors Which May Influence Future Operations**

Our long-term corporate strategy is to continue to focus on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry. As of June 30, 2009, our operating portfolio was 77.0% leased to 127 tenants. As of December 31, 2008, our operating portfolio was 86.9% leased to 115 tenants. The decrease in the overall leasing percentage is a reflection of an increase in the rentable square footage in our operating portfolio, which increased by approximately 2.3 million rentable square feet in the six months ended June 30, 2009 due to the completion of development or redevelopment activities at a number of properties.

Leases representing approximately 3.4% of our leased square footage expire during the remainder of 2009 (including month-to-month leases) and leases representing approximately 7.3% of our leased square footage expire during 2010. Our leasing strategy for 2009 focuses on leasing currently vacant space and negotiating renewals for leases scheduled to expire during the year, and identifying new tenants or existing tenants seeking additional space to occupy the spaces for which we are unable to negotiate such renewals. The success of our leasing and development strategy will depend upon the general economic conditions in the United States and in our target markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania, New York/New Jersey and research parks near or adjacent to universities. We may proceed with additional new developments, as real estate and capital market conditions permit.



It is generally acknowledged that the United States has been in an economic recession since the fourth quarter of 2007. The recession has been accompanied by a severe tightening of credit and capital markets that have significantly increased our cost of capital. Our ability to raise debt and equity capital has contributed to our successful growth strategy. However, over the past twelve months, we have, as have REITs in general, focused on deleveraging and preserving capital. While we expect to be able to continue to raise debt capital, we expect that such debt will carry significantly higher interest rates and lower advance rates measured on a ratio of loan-to-value.

During the past six months, we have also seen an increase in bankruptcies from certain tenants that are not well capitalized and an increase in tenants seeking to terminate existing lease arrangements. To date, we have not been significantly affected by tenant bankruptcies or lease terminations because space associated with leases terminated by tenants (either voluntarily or due to bankruptcy) has already been subleased (and we will enter into direct leases with subtenants) or can be re-leased, or we are receiving termination payments compensating us for a portion of lost rents. However, there can be no assurance that recent trends in lease terminations will not continue and, if they do, that we will be able to continue to materially mitigate the effects of any such terminations.

As a direct result of the current economic recession, we believe it is possible that the fair-values of some of our properties may have declined below their respective carrying values. However, to the extent that a property has a substantial remaining estimated useful life and management does not believe that it is more likely than not the property will be disposed of prior to the end of its useful life, it would be unusual for undiscounted cash flows to be insufficient to recover the property's carrying value. We presently have the ability and intent to continue to own and operate our existing portfolio of properties and expected undiscounted future cash flows from the operation of the properties are expected to be sufficient to recover the carrying value of each property. Accordingly, we do not believe that the carrying value of any of our properties is impaired. If our ability and/or our intent with regard to the operation of our properties otherwise dictate an earlier sale date, an impairment loss may be recognized to reduce the property to the lower of the carrying amount or fair-value less costs to sell, and such loss could be material.

A discussion of additional factors which may influence future operations can be found below under Part II, Item 1A, Risk Factors and in our annual report on Form 10-K for the year ended December 31, 2008.

**Table of Contents****Critical Accounting Policies**

A complete discussion of our critical accounting policies can be found in our annual report on Form 10-K for the year ended December 31, 2008.

**New Accounting Standards**

See Notes to Consolidated Financial Statements (Unaudited) included elsewhere herein for disclosure of new accounting standards.

**Results of Operations****Comparison of the Three Months Ended June 30, 2009 to the Three Months Ended June 30, 2008**

The following table sets forth the basis for presenting the historical financial information for same properties (all properties except redevelopment/development and new properties), redevelopment/development properties (properties that were entirely or primarily under redevelopment or development during either of the three months ended June 30, 2009 or 2008), new properties (properties that were not owned for each of the three months ended June 30, 2009 and 2008 and were not under redevelopment/development), and corporate entities (legal entities performing general and administrative functions and fees received from our PREI joint ventures), in thousands:

|                   | <b>Redevelopment/Development</b> |             |                   |             | <b>New</b>        |             | <b>Corporate</b> |             |
|-------------------|----------------------------------|-------------|-------------------|-------------|-------------------|-------------|------------------|-------------|
|                   | <b>Same Properties</b>           |             | <b>Properties</b> |             | <b>Properties</b> |             |                  |             |
|                   | <b>2009</b>                      | <b>2008</b> | <b>2009</b>       | <b>2008</b> | <b>2009</b>       | <b>2008</b> | <b>2009</b>      | <b>2008</b> |
| Rental            | \$ 51,347                        | \$ 49,926   | \$ 14,367         | \$ 4,301    | \$                | \$          | \$ 2             | \$ (4)      |
| Tenant recoveries | 12,940                           | 14,594      | 4,027             | 1,094       |                   |             | 222              | 116         |
| Other income      | 2,670                            | 21          | 5                 |             |                   |             | 500              | 723         |
| Total revenues    | \$ 66,957                        | \$ 64,541   | \$ 18,399         | \$ 5,395    | \$                | \$          | \$ 724           | \$ 835      |

**Rental Revenues.** Rental revenues increased \$11.5 million to \$65.7 million for the three months ended June 30, 2009 compared to \$54.2 million for the three months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property). Same property rental revenues increased \$1.4 million, or 2.8%, for the three months ended June 30, 2009 compared to the same period in 2008. The increase in same property rental revenues was primarily a result of the commencement of new leases at certain properties in 2009, and increases in lease rates related to CPI adjustments and lease extensions (increasing rental revenue recognized on a straight-line basis), partially offset by lease expirations and early lease terminations.

**Tenant Recoveries.** Revenues from tenant reimbursements increased \$1.4 million to \$17.2 million for the three months ended June 30, 2009 compared to \$15.8 million for the three months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property), partially offset by changes in 2008 at certain properties at which the tenant began to pay vendors directly for certain recoverable expenses. Same property tenant recoveries decreased \$1.7 million, or 11.3%, for the three months ended June 30, 2009 compared to the same period in 2008 primarily as a result of changes in 2008 at certain properties at which the tenant began to pay vendors directly for certain recoverable expenses and early lease terminations.

The percentage of recoverable expenses recovered at our properties decreased to 77.2% for the three months ended June 30, 2009 compared to 86.0% for the three months ended June 30, 2008, primarily due to properties that were placed in service in 2009, but were not fully leased, and properties for which leases commenced in 2008 and 2009, but for which payment for recoverable expenses will not begin until a later period. In addition, property recovery percentages were affected by an increase in the rental operations expense of approximately \$520,000 related to early lease terminations.

**Other Income.** Other income was \$3.2 million for the three months ended June 30, 2009 compared to \$744,000 for the three months ended June 30, 2008. Other income for the three months ended June 30, 2009 was primarily comprised

of consideration received related to early lease terminations of approximately \$2.6 million and development fees earned from our PREI joint ventures. Other income for the three months ended June 30, 2008 was primarily comprised of development fees related to our PREI joint ventures.

**Table of Contents**

The following table shows operating expenses for same properties, redevelopment/development properties, new properties, and corporate entities, in thousands:

|                               | <b>Redevelopment/Development</b> |             |                   |             |                       |             |                  |             |
|-------------------------------|----------------------------------|-------------|-------------------|-------------|-----------------------|-------------|------------------|-------------|
|                               | <b>Same Properties</b>           |             | <b>Properties</b> |             | <b>New Properties</b> |             | <b>Corporate</b> |             |
|                               | <b>2009</b>                      | <b>2008</b> | <b>2009</b>       | <b>2008</b> | <b>2009</b>           | <b>2008</b> | <b>2009</b>      | <b>2008</b> |
| Rental operations             | \$ 10,156                        | \$ 11,686   | \$ 2,808          | \$ 1,068    | \$                    | \$          | \$ 1,697         | \$ 700      |
| Real estate taxes             | 5,299                            | 4,541       | 2,314             | 372         |                       |             |                  | 2           |
| Depreciation and amortization | 17,184                           | 17,615      | 7,317             | 1,716       |                       |             |                  |             |
| Total expenses                | \$ 32,639                        | \$ 33,842   | \$ 12,439         | \$ 3,156    | \$                    | \$          | \$ 1,697         | \$ 702      |

*Rental Operations Expense.* Rental operations expense increased \$1.2 million to \$14.7 million for the three months ended June 30, 2009 compared to \$13.5 million for the three months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property), partially offset by changes in 2008 at certain properties at which the tenant began to pay vendors directly for certain recoverable expenses. Same property rental operations expense decreased \$1.5 million, or 13.1%, for the three months ended June 30, 2009 compared to the same period in 2008 primarily due to a change in 2008 at certain properties at which the tenant began to pay vendors directly for certain recoverable expenses and net decreases in utility usage and other recoverable costs compared to the same period in the prior year, partially offset by the write-off of certain assets related to early lease terminations.

*Real Estate Tax Expense.* Real estate tax expense increased \$2.7 million to \$7.6 million for the three months ended June 30, 2009 compared to \$4.9 million for the three months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development in the prior year for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property). Same property real estate tax expense increased \$758,000, or 16.7%, for the three months ended June 30, 2009 compared to the same period in 2008 primarily due to a tax refund received in 2008 and applied to one property and other successful tax appeals in the prior year and increases in assessments in 2009 at certain properties.

*Depreciation and Amortization Expense.* Depreciation and amortization expense increased \$5.2 million to \$24.5 million for the three months ended June 30, 2009 compared to \$19.3 million for the three months ended June 30, 2008. The increase was primarily due to commencement of partial operations and recognition of depreciation and amortization expense at certain of our redevelopment and development properties in 2008 and 2009 (principally at our Center for Life Science | Boston property).

*General and Administrative Expenses.* General and administrative expenses decreased \$519,000 to \$5.1 million for the three months ended June 30, 2009 compared to \$5.6 million for the three months ended June 30, 2008. The decrease was primarily due to lower amounts of compensation expense for senior management due to the retirement of one of our founders in December 2008.

*Equity in Net (Loss)/Income of Unconsolidated Partnerships.* Equity in net (loss)/income of unconsolidated partnerships increased \$508,000 to a loss of \$(465,000) for the three months ended June 30, 2009 compared to income of \$43,000 for the three months ended June 30, 2008. The increase was primarily due to cessation of the capitalization of interest and operating expenses at certain properties of our PREI joint ventures, which were placed in service in 2008.

*Interest Expense.* Interest cost incurred for the three months ended June 30, 2009 totaled \$16.3 million compared to \$20.9 million (revised for adoption of FSP 14-1, which increased interest cost by approximately \$683,000) for the three months ended June 30, 2008. Total interest cost incurred decreased primarily as a result of: (a) decreases in borrowings for working capital purposes, (b) the repayment of certain mortgage notes and (c) decreases in the average

interest rate on our outstanding borrowings.

During the three months ended June 30, 2009, we capitalized \$3.5 million of interest compared to \$11.8 million (revised for adoption of FSP 14-1, which increased capitalized interest by approximately \$348,000) for the three months ended June 30, 2008. The decrease reflects the partial or complete cessation of capitalized interest at our Center for Life Science | Boston, 9865 Towne Centre Drive, and 530 Fairview Avenue development projects and our Pacific Research Center redevelopment project due to the commencement of certain leases at those properties or the cessation of development or redevelopment activities. We expect capitalized interest costs on these and other properties currently under development or redevelopment to decrease or cease as rentable space at these properties is readied for its intended uses through 2009. Net of capitalized interest and the accretion of debt premiums and a debt discount, interest expense increased \$3.9 million to \$12.9 million for the three months ended June 30, 2009 compared to \$9.0 million for the three months ended June 30, 2008. We expect interest expense to continue to increase in 2009 as additional properties currently under development or redevelopment are readied for their intended uses and placed in service, from higher interest expense associated with a new fixed-rate mortgage loan secured by our Center for Life Science | Boston property used to repay a portion of the variable-rate secured construction loan (see Note 4 of the footnotes to the consolidated financial statements), and from the amortization of the unrealized losses of approximately \$66.9 million deferred in other comprehensive income related to the forward starting swaps, which will be amortized as additional interest expense over a 10-year term.

**Table of Contents**

*Gain on Derivative Instruments.* During the three months ended June 30, 2009, approximately \$360,000 of gains from changes in the fair-value of derivative instruments were recognized as gain on derivative instruments in the consolidated statements of income (changes in the fair value net of ineffectiveness of \$485,000 related to an ineffective forward starting swap, partially offset by ineffectiveness of approximately \$125,000 on cash flow hedges due to mismatches in forecasted debt issuance dates, maturity dates and interest rate reset dates of the interest rate and forward starting swaps and related debt).

*Gain on Extinguishment of Debt.* During the three months ended June 30, 2009, we repurchased \$8.8 million face value of our exchangeable senior notes for approximately \$5.7 million. The repurchase resulted in the recognition of a gain on extinguishment of debt of approximately \$2.6 million (net of the write-off of approximately \$510,000 in deferred loan fees and unamortized debt discount), partially offset by the write-off of approximately \$843,000 of deferred loan fees related to the repayment of our secured construction loan in June 2009, which is reflected in our consolidated statements of income.

*Noncontrolling Interests.* Income attributable to noncontrolling interests increased \$25,000 to \$645,000 for the three months ended June 30, 2009 compared to \$620,000 for the three months ended June 30, 2008. The increase in noncontrolling interests was due to the increase in net income.

***Comparison of the Six Months Ended June 30, 2009 to the Six Months Ended June 30, 2008***

The following table sets forth the basis for presenting the historical financial information for same properties (all properties except redevelopment/development and new properties), redevelopment/development properties (properties that were entirely or primarily under redevelopment or development during either of the six months ended June 30, 2009 or 2008), new properties (properties that were not owned for each of the six months ended June 30, 2009 and 2008 and were not under redevelopment/development), and corporate entities (legal entities performing general and administrative functions and fees received from our PREI joint ventures), in thousands:

|                       | <b>Redevelopment/Development</b> |                   |                   |                 |                       |               |                  |                 |
|-----------------------|----------------------------------|-------------------|-------------------|-----------------|-----------------------|---------------|------------------|-----------------|
|                       | <b>Same Properties</b>           |                   | <b>Properties</b> |                 | <b>New Properties</b> |               | <b>Corporate</b> |                 |
|                       | <b>2009</b>                      | <b>2008</b>       | <b>2009</b>       | <b>2008</b>     | <b>2009</b>           | <b>2008</b>   | <b>2009</b>      | <b>2008</b>     |
| Rental                | \$ 105,422                       | \$ 98,887         | \$ 28,422         | \$ 5,435        | \$ 294                | \$ 251        | \$ (3)           | \$ (8)          |
| Tenant recoveries     | 27,816                           | 30,638            | 10,058            | 1,468           | 27                    | 14            | 369              | 266             |
| Other income          | 6,570                            | 157               | 10                | 1               | 4                     |               | 1,042            | 1,020           |
| <b>Total revenues</b> | <b>\$ 139,808</b>                | <b>\$ 129,682</b> | <b>\$ 38,490</b>  | <b>\$ 6,904</b> | <b>\$ 325</b>         | <b>\$ 265</b> | <b>\$ 1,408</b>  | <b>\$ 1,278</b> |

*Rental Revenues.* Rental revenues increased \$29.5 million to \$134.1 million for the six months ended June 30, 2009 compared to \$104.6 million for the six months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property) and the commencement of leases. Same property rental revenues increased \$6.5 million, or 6.6%, for the six months ended June 30, 2009 compared to the same period in 2008. The increase in same property rental revenues was primarily a result of the acceleration of the amortization of below-market lease intangible assets related to lease terminations of approximately \$2.6 million, the commencement of new leases at certain properties in 2009, and increases in lease rates related to CPI adjustments lease extensions (increasing rental revenue recognized on a straight-line basis), partially offset by lease expirations and early lease terminations.

*Tenant Recoveries.* Revenues from tenant reimbursements increased \$5.9 million to \$38.3 million for the six months ended June 30, 2009 compared to \$32.4 million for the six months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property), partially offset by changes in 2008 at certain properties at which the tenant began to pay vendors directly for certain recoverable expenses. Same property tenant recoveries decreased \$2.8 million, or 9.2%, for the six months ended June 30, 2009 compared to the same period in 2008 primarily as a result of changes in 2008 at certain properties at which the tenant began to pay

vendors directly for certain recoverable expenses and early lease terminations.

The percentage of recoverable expenses recovered at our properties decreased to 73.3% for the six months ended June 30, 2009 compared to 86.4% for the six months ended June 30, 2008, primarily due to properties that were placed in service in 2009, but were not fully leased, and properties for which leases commenced in 2008 and 2009, but for which payment for recoverable expenses will not begin until a later period. In addition, property recovery percentages were affected by an increase in the rental operations expense of approximately \$4.2 million related to early lease terminations.

**Table of Contents**

*Other Income.* Other income was \$7.6 million for the six months ended June 30, 2009 compared to \$1.2 million for the six months ended June 30, 2008. Other income for the six months ended June 30, 2009 was primarily comprised of consideration received related to early lease terminations of approximately \$6.5 million and development fees earned from our PREI joint ventures. Other income for the six months ended June 30, 2008 was primarily comprised of development fees related to our PREI joint ventures.

The following table shows operating expenses for same properties, redevelopment/development properties, new properties, and corporate entities, in thousands:

|                               | <b>Redevelopment/Development</b> |             |                   |             |                       |             |                  |             |
|-------------------------------|----------------------------------|-------------|-------------------|-------------|-----------------------|-------------|------------------|-------------|
|                               | <b>Same Properties</b>           |             | <b>Properties</b> |             | <b>New Properties</b> |             | <b>Corporate</b> |             |
|                               | <b>2009</b>                      | <b>2008</b> | <b>2009</b>       | <b>2008</b> | <b>2009</b>           | <b>2008</b> | <b>2009</b>      | <b>2008</b> |
| Rental operations             | \$ 24,788                        | \$ 23,851   | \$ 8,706          | \$ 1,364    | \$ 612                | \$ 513      | \$ 2,707         | \$ 1,590    |
| Real estate taxes             | 10,154                           | 9,549       | 4,670             | 615         | 22                    | 19          |                  | 2           |
| Depreciation and amortization | 37,383                           | 34,430      | 14,006            | 2,236       | 424                   | 352         |                  |             |
| Total expenses                | \$ 72,325                        | \$ 67,830   | \$ 27,382         | \$ 4,215    | \$ 1,058              | \$ 884      | \$ 2,707         | \$ 1,592    |

*Rental Operations Expense.* Rental operations expense increased \$9.5 million to \$36.8 million for the six months ended June 30, 2009 compared to \$27.3 million for the six months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property) and the write-off of certain assets related to early lease terminations of approximately \$4.2 million. Same property rental operations expense increased \$937,000, or 3.9%, for the six months ended June 30, 2009 compared to the same period in 2008 primarily due to a change in 2008 at certain properties at which the tenant began to pay vendors directly for certain recoverable expenses and net decreases in utility usage and other recoverable costs compared to the same period in the prior year, partially offset by the write-off of certain assets related to early lease terminations.

*Real Estate Tax Expense.* Real estate tax expense increased \$4.6 million to \$14.8 million for the six months ended June 30, 2009 compared to \$10.2 million for the six months ended June 30, 2008. The increase was primarily due to properties that were under redevelopment or development in the prior year for which partial revenue recognition commenced during 2008 and 2009 (principally at our Center for Life Science | Boston property). Same property real estate tax expense increased \$605,000, or 6.3%, for the six months ended June 30, 2009 compared to the same period in 2008 primarily due to a tax refund received in 2008 and applied to one property and other successful tax appeals in the prior year and increases in assessments in 2009 at certain properties.

*Depreciation and Amortization Expense.* Depreciation and amortization expense increased \$14.8 million to \$51.8 million for the six months ended June 30, 2009 compared to \$37.0 million for the six months ended June 30, 2008. The increase was primarily due to commencement of partial operations and recognition of depreciation and amortization expense at certain of our redevelopment and development properties in 2008 and 2009 (principally at our Center for Life Science | Boston property) and the acceleration of depreciation on certain assets related to early lease terminations of approximately \$4.0 million.

*General and Administrative Expenses.* General and administrative expenses decreased \$1.4 million to \$10.4 million for the six months ended June 30, 2009 compared to \$11.8 million for the six months ended June 30, 2008. The decrease was primarily due to lower amounts of compensation expense for senior management due to the retirement of one of our founders in December 2008.

*Equity in Net Loss of Unconsolidated Partnerships.* Equity in net loss of unconsolidated partnerships increased \$636,000 to \$766,000 for the six months ended June 30, 2009 compared to \$130,000 for the six months ended June 30, 2008. The increase was primarily due to cessation of the capitalization of interest and operating expenses at certain properties of our PREI joint ventures that were placed in service in 2008.



*Interest Expense.* Interest cost incurred for the six months ended June 30, 2009 totaled \$32.6 million compared to \$43.1 million (revised for adoption of FSP 14-1, which increased interest cost by approximately \$1.3 million) for the six months ended June 30, 2008. Total interest cost incurred decreased primarily as a result of: (a) decreases in borrowings for working capital purposes, (b) the repayment of certain mortgage notes and (c) decreases in the average interest rate on our outstanding borrowings.

During the six months ended June 30, 2009, we capitalized \$7.6 million of interest compared to \$26.9 million (revised for adoption of FSP 14-1, which increased capitalized interest by approximately \$757,000) for the six months ended June 30, 2008. The decrease reflects the partial or complete cessation of capitalized interest at our Center for Life Science | Boston, 9865 Towne Centre Drive, and 530 Fairview Avenue development projects and our Pacific Research Center redevelopment project due to the commencement of certain leases at those properties or the cessation of development or redevelopment activities. We expect capitalized interest costs on these and other properties currently under development or redevelopment to decrease or cease as rentable space at these properties is readied for its intended uses through 2009. Net of capitalized interest and the accretion of debt premiums and a debt discount, interest expense increased \$8.8 million to \$25.0 million for the six months ended June 30, 2009 compared to \$16.2 million for the six months ended June 30, 2008. We expect interest expense to continue to increase in 2009 as additional properties currently under development or redevelopment are readied for their intended uses and placed in service, from higher interest expense associated with debt secured by our Center for Life Science | Boston property as a result of the repayment of the variable-rate secured construction loan and the closing of fixed-rate mortgage loan (see Note 4 in the footnotes to the consolidated financial statements), and the amortization of the unrealized losses of approximately \$66.9 million deferred in other comprehensive income related to the forward starting swaps, which will be amortized as additional interest expense over a 10-year term.

**Table of Contents**

*Gain on Derivative Instruments.* During the six months ended June 30, 2009, a portion of the unrealized losses related to the \$100.0 million forward starting swap previously included in accumulated other comprehensive loss, totaling approximately \$4.5 million, was reclassified to the consolidated statements of income as loss on derivative instruments as a result of a change in the amount of forecasted debt issuance relating to the forward starting swaps, from \$400.0 million at December 31, 2008 to \$368.0 million at June 30, 2009. The gain on derivative instruments for the six months ended June 30, 2009 also includes gains from changes in the fair-value of derivative instruments (net of hedge ineffectiveness of approximately \$488,000 on cash flow hedges due to mismatches in forecasted debt issuance dates, maturity dates and interest rate reset dates of the interest rate and forward starting swaps and related debt).

*Gain on Extinguishment of Debt.* During the six months ended June 30, 2009, we repurchased \$20.8 million face value of our exchangeable senior notes for approximately \$12.6 million. The repurchase resulted in the recognition of a gain on extinguishment of debt of approximately \$7.0 million (net of the write-off of approximately \$1.2 million in deferred loan fees and unamortized debt discount), partially offset by the write-off of approximately \$843,000 of deferred loan fees related to the repayment of our secured construction loan in June 2009, which is reflected in our consolidated statements of income.

*Noncontrolling Interests.* Income attributable to noncontrolling interests increased \$148,000 to \$1.4 million for the six months ended June 30, 2009 compared to \$1.2 million for the six months ended June 30, 2008. The increase in noncontrolling interests was due to the increase in net income, partially offset by an increase in the net loss in noncontrolling interests in our consolidated partnerships for the six months ended June 30, 2009.

**Cash Flows*****Comparison of the Six Months Ended June 30, 2009 to the Six Months Ended June 30, 2008***

|   | 2009      | 2008<br>(Revised)<br>(In thousands) | Change    |
|---|-----------|-------------------------------------|-----------|
| Net cash provided by operating activities | \$ 72,685 | \$ 52,338                           | \$ 20,347 |
| Net cash used in investing activities     | (101,535) | (134,456)                           | 32,921    |
| Net cash provided by financing activities | 41,529    | 89,996                              | (48,467)  |
| Ending cash and cash equivalents balance  | 34,101    | 21,357                              | 12,744    |

Net cash provided by operating activities increased \$20.4 million to \$72.7 million for the six months ended June 30, 2009 compared to \$52.3 million for the six months ended June 30, 2008. The increase was primarily due to an increase in net income before depreciation and amortization and changes in operating assets and liabilities.

Net cash used in investing activities decreased \$32.9 million to \$101.5 million for the six months ended June 30, 2009 compared to \$134.4 million for the six months ended June 30, 2008. The decrease was primarily due to decreases in the purchases of interests in investments in real estate and additions to non-real estate assets (primarily related to our relocation to a new corporate headquarters in 2008), partially offset by higher contributions to unconsolidated partnerships (primarily related to the refinancing of the PREI joint ventures secured acquisition and interim loan facility).

Net cash provided by financing activities decreased \$48.5 million to \$41.5 million for the six months ended June 30, 2009 compared to \$90.0 million for the six months ended June 30, 2008. The decrease was primarily due to the repayment of the construction loan and settlement of derivative instruments, partially offset by borrowings on our unsecured line of credit and newly issued mortgage loans.

**Table of Contents****Funds from Operations**

We present funds from operations, or FFO, available to common shares and partnership and LTIP units because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides a performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.

Our FFO available to common shares and partnership and LTIP units and a reconciliation to net income attributable to common stockholders (in thousands, except share data) was as follows:

|   | <b>Three Months Ended</b> |                  | <b>Six Months Ended</b> |                  |
|---|---------------------------|------------------|-------------------------|------------------|
|   | <b>June 30,</b>           |                  | <b>June 30,</b>         |                  |
|   | <b>2009</b>               | <b>2008</b>      | <b>2009</b>             | <b>2008</b>      |
|   |                           | <b>(Revised)</b> |                         | <b>(Revised)</b> |
| Net income available to common stockholders   | \$ 18,195                 | \$ 13,705        | \$ 37,219               | \$ 26,036        |
| Adjustments:  |                           |                  |                         |                  |
| Noncontrolling interests in operating partnership   | 658                       | 619              | 1,380                   | 1,209            |
| Depreciation and amortization unconsolidated partnerships   | 662                       | 450              | 1,323                   | 901              |
| Depreciation and amortization consolidated entities   | 24,501                    | 19,331           | 51,813                  | 37,018           |
| Depreciation and amortization allocable to noncontrolling interest of consolidated joint ventures | (19)                      | (8)              | (39)                    | (16)             |
| Funds from operations available to common shares and Units  | \$ 43,997                 | \$ 34,097        | \$ 91,696               | \$ 65,148        |
| Funds from operations per share diluted   | \$ 0.48                   | \$ 0.46          | \$ 1.04                 | \$ 0.91          |
| Weighted-average common shares and Units outstanding diluted                                      | 92,615,935                | 73,811,597       | 88,580,072              | 71,418,266       |

**Liquidity and Capital Resources**

Our short-term liquidity requirements consist primarily of funds to pay for future distributions expected to be paid to our stockholders, swap settlements, operating expenses and other expenditures directly associated with our properties, interest expense and scheduled principal payments on outstanding mortgage indebtedness, general and administrative expenses, capital expenditures, tenant improvements and leasing commissions. As a result of the repayment of the secured construction loan in June 2009, we have no debt maturities coming due through the remainder of 2009.

**Table of Contents**

The remaining principal payments due for our consolidated and our proportionate share of unconsolidated indebtedness (mortgage notes payable excluding the debt premium of \$7.9 million, unsecured line of credit, secured term loan, the Notes excluding the debt discount of \$4.3 million, and our proportionate share of outstanding unconsolidated indebtedness) as of June 30, 2009 were as follows:

|   | <b>2009</b>     | <b>2010</b>      | <b>2011</b>       | <b>2012</b>       | <b>2013</b>      | <b>Thereafter</b> | <b>Total</b>        |
|---|-----------------|------------------|-------------------|-------------------|------------------|-------------------|---------------------|
| Fixed-rate mortgages                          | \$ 3,884        | \$ 50,842        | \$ 29,891         | \$ 45,383         | \$ 26,051        | \$ 553,810        | \$ 709,861          |
| Unsecured line of credit                      |                 |                  | 292,404           |                   |                  |                   | 292,404             |
| Secured term loan                             |                 |                  |                   | 250,000           |                  |                   | 250,000             |
| Notes   |                 |                  |                   |                   |                  | 107,420           | 107,420             |
| <b>Total consolidated indebtedness</b>        | <b>\$ 3,884</b> | <b>\$ 50,842</b> | <b>\$ 322,295</b> | <b>\$ 295,383</b> | <b>\$ 26,051</b> | <b>\$ 661,230</b> | <b>\$ 1,359,685</b> |
| Secured acquisition and interim loan facility | \$              | \$               | \$ 40,650         | \$                | \$               | \$                | \$ 40,650           |
| Secured construction loan                     |                 | 33,634           |                   |                   |                  |                   | 33,634              |
| McKellar Court fixed-rate mortgage            | 17              | 2,142            |                   |                   |                  |                   | 2,159               |
| <b>Total unconsolidated indebtedness</b>      | <b>\$ 17</b>    | <b>\$ 35,776</b> | <b>\$ 40,650</b>  | <b>\$</b>         | <b>\$</b>        | <b>\$</b>         | <b>\$ 76,443</b>    |
| <b>Total indebtedness</b>                     | <b>\$ 3,901</b> | <b>\$ 86,618</b> | <b>\$ 362,945</b> | <b>\$ 295,383</b> | <b>\$ 26,051</b> | <b>\$ 661,230</b> | <b>\$ 1,436,128</b> |

In April 2009, we settled our remaining forward starting swaps with the corresponding counterparties for approximately \$77.6 million. The forward starting swaps were entered into to mitigate our exposure to the variability in expected future cash flows attributable to changes in future interest rates associated with a forecasted issuance of fixed-rate debt, which occurred in June 2009 when we closed on fixed-rate mortgage loans secured by our 9865 Towne Centre Drive and Center for Life Science | Boston properties (see Note 4). The unrealized losses of \$66.9 million will be amortized as additional interest expense over a 10-year term.

Our long-term liquidity requirements consist primarily of funds to pay for scheduled debt maturities, construction obligations, renovations, expansions, capital commitments and other non-recurring capital expenditures that need to be made periodically, and the costs associated with acquisitions of properties that we pursue.

We expect to satisfy our short-term liquidity requirements through our existing working capital and cash provided by our operations, long-term secured and unsecured indebtedness, the issuance of additional equity or debt securities and the use of net proceeds from the disposition of non-strategic assets. Our rental revenues, provided by our leases, generally provide cash inflows to meet our debt service obligations, pay general and administrative expenses, and fund regular distributions. We expect to satisfy our long-term liquidity requirements through our existing working capital, cash provided by operations, long-term secured and unsecured indebtedness, the issuance of additional equity or debt securities and the use of net proceeds from the disposition of non-strategic assets. We also expect to use funds available under our unsecured line of credit to finance acquisition and development activities and capital expenditures on an interim basis. Continued uncertainty in the credit markets may negatively impact our ability to access additional debt financing or to refinance existing debt maturities on favorable terms (or at all), which may negatively affect our ability to make acquisitions and fund current and future development and redevelopment projects. In addition, the financial positions of the lenders under our credit facilities may worsen to the point that they default on their obligations to make available to us the funds under those facilities. A prolonged downturn in the credit markets may cause us to seek alternative sources of potentially less attractive financing, and may require us to adjust our business

plans accordingly.

On February 11, 2009, our PREI joint ventures jointly refinanced the outstanding balance of the secured acquisition and interim loan facility, or approximately \$364.1 million, with the proceeds of a new loan totaling \$203.3 million and members' capital contributions funding the balance due. The new loan bears interest at a rate equal to, at the option of our PREI joint ventures, either (1) reserve adjusted LIBOR plus 350 basis points or (2) the higher of (a) the prime rate then in effect, (b) the federal funds rate then in effect plus 50 basis points or (c) one-month LIBOR plus 450 basis points, and requires interest only monthly payments until the maturity date, February 10, 2011. The loan includes certain restrictions and covenants that limit, among other things, the incurrence of additional indebtedness and liens at our PREI joint ventures. In addition, our PREI joint ventures may extend the maturity date of the secured acquisition and interim loan facility to February 10, 2012 after satisfying certain conditions and paying an extension fee based on the then current facility commitment.

In March 2009, we completed the repurchase of \$12.0 million face value of our exchangeable senior notes for approximately \$6.9 million. In April 2009, we completed the repurchase of an additional \$8.8 million face value of our exchangeable senior notes for approximately \$5.7 million.

On May 21, 2009, we completed the issuance of 16,754,854 shares of common stock, including the exercise of an over-allotment option of 754,854 shares, resulting in net proceeds of approximately \$166.9 million, after deducting the underwriters' discount and commissions and offering expenses. The net proceeds were utilized to repay a portion of the outstanding indebtedness on our unsecured line of credit and for other general corporate and working capital purposes.

**Table of Contents**

On June 19, 2009, we closed on an \$18.0 million mortgage loan, which is secured by our 9865 Towne Centre Drive property in San Diego, California. The mortgage loan bears interest at a fixed-rate of 7.95% per annum and matures in June 2013.

On June 29, 2009, we closed on a \$350.0 million mortgage loan, which is secured by our Center for Life Science I Boston property in Boston, Massachusetts. The mortgage loan bears interest at a fixed-rate of 7.75% per annum and matures in June 2014. We utilized the net proceeds from the new mortgage loan, along with borrowings from our unsecured line of credit, to repay the outstanding \$507.1 million secured construction loan, which was secured by the Center for Life Science I Boston property. The new loan includes a financial covenant relating to a minimum amount of net worth. We believe that we were in compliance with this covenant as of June 30, 2009.

Under the rules adopted by the Securities and Exchange Commission regarding registration and offering procedures, if we meet the definition of a well-known seasoned issuer under Rule 405 of the Securities Act of 1933, as amended, or Securities Act, we are permitted to file an automatic shelf registration statement that will be immediately effective upon filing. On September 15, 2006, we filed such an automatic shelf registration statement, which may permit us, from time to time, to offer and sell debt securities, common stock, preferred stock, warrants and other securities to the extent necessary or advisable to meet our liquidity needs.

Our total capitalization at June 30, 2009 was approximately \$2.6 billion and was comprised of the following:

|  | <b>Shares/Units at<br/>June 30, 2009</b> | <b>Aggregate<br/>Principal<br/>Amount or<br/>Dollar Value<br/>Equivalent<br/>(In thousands)</b> | <b>Percent of<br/>Total<br/>Capitalization</b> |
|--|--|---|--|
| <b>Debt:</b>                                     |  |   |  |
| Mortgage notes payable (1)                       |  | \$ 717,764  | 27.3%  |
| Secured term loan                                |  | 250,000   | 9.5%   |
| Exchangeable senior notes (2)                    |  | 103,077   | 3.9%   |
| Unsecured line of credit                         |  | 292,404   | 11.1%  |
| <b>Total debt</b>                                |  | <b>1,363,245</b>  | <b>51.8%</b>                                   |
| <b>Equity:</b>                                   |  |   |  |
| Common shares outstanding (3)                    | 98,118,639                               | 1,003,754   | 38.3%  |
| 7.375% Series A Preferred shares outstanding (4) | 9,200,000                                | 230,000   | 8.7%   |
| Operating partnership units outstanding (5)      | 2,607,164                                | 26,671  | 1.0%   |
| LTIP units outstanding (5)                       | 566,540                                  | 5,796   | 0.2%   |
| <b>Total equity</b>                              |  | <b>1,266,221</b>  | <b>48.2%</b>                                   |
| <b>Total capitalization</b>                      |  | <b>\$ 2,629,466</b>   | <b>100.0%</b>                                  |

(1) Amount includes debt premiums of \$7.9 million recorded upon

the assumption of the outstanding indebtedness in connection with our purchase of the corresponding properties.

- (2) Amount includes a debt discount of \$4.3 million recorded in accordance with FSP 14-1.
- (3) Based on the market closing price of our common stock of \$10.23 per share on the last trading day of the quarter (June 30, 2009).
- (4) Based on the liquidation preference of \$25.00 per share for our 7.375% Series A preferred stock.
- (5) Our partnership and LTIP units are each individually convertible into one share of common stock using the market closing price of our common stock of \$10.23 per share on the last trading day of the quarter (June 30, 2009).



Our board of directors has adopted a policy of targeting our indebtedness at approximately 50% of our total asset book value. At June 30, 2009, the ratio of debt to total asset book value was approximately 41.2%. However, our board of directors may from time to time modify our debt policy in light of economic or market conditions including, but not limited to, the relative costs of debt and equity capital, market conditions for debt and equity securities and fluctuations in the market price of our common stock. Accordingly, we may increase or decrease our debt to total asset book value ratio beyond the limit described above.

We may from time to time seek to repurchase or redeem our outstanding debt, shares of common stock or preferred stock or other securities in open market purchases, privately negotiated transactions or otherwise. Such repurchases or redemptions, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors.

**Table of Contents****Off-Balance Sheet Arrangements**

As of June 30, 2009, we had investments in the following unconsolidated partnerships: (1) McKellar Court limited partnership, which owns a single tenant occupied property located in San Diego; and (2) two limited liability companies with PREI, which own a portfolio of properties located in Cambridge, Massachusetts (see Note 8).

McKellar Court is a variable interest entity as defined in FIN 46R; however, we are not the primary beneficiary. The limited partner at McKellar Court is the only tenant in the property and will bear a disproportionate amount of any losses. We, as the general partner, will receive 21% of the operating cash flows and 75% of the gains upon sale of the property. We account for our general partner interest using the equity method. The assets of McKellar Court were \$16.0 million and \$16.2 million at June 30, 2009 and December 31, 2008, respectively, and the liabilities were \$10.6 million at both June 30, 2009 and December 31, 2008. Our equity in net income of McKellar Court was \$22,000 and \$20,000 for the three months ended June 30, 2009 and 2008, respectively, and \$42,000 and \$41,000 for the six months ended June 30, 2009 and 2008, respectively.

PREI II LLC is a variable interest entity as defined in FIN 46R; however, we are not the primary beneficiary. PREI will bear the majority of any losses incurred. PREI I LLC does not qualify as a variable interest entity as defined in FIN 46R. In addition, consolidation under EITF 04-5 is not required as we do not control the limited liability companies. In connection with the formation of the PREI limited liability companies in April 2007, we contributed 20% of the initial capital. However, the amount of cash flow distributions that we may receive may be more or less based on the nature of the circumstances underlying the cash distributions due to provisions in the operating agreements governing the distribution of funds to each member and the occurrence of extraordinary cash flow events. We account for our member interests using the equity method for both limited liability companies. The assets of the PREI limited liability companies were \$630.4 million and \$614.2 million and the liabilities were \$392.5 million and \$532.1 million at June 30, 2009 and December 31, 2008, respectively. Our equity in net (loss)/income of the PREI limited liability companies (net of intercompany eliminations) was a loss of \$486,000 and net income of \$22,000 for the three months ended June 30, 2009 and 2008, respectively, and losses of \$807,000 and \$169,000 for the six months ended June 30, 2009 and 2008, respectively.

We have been the primary beneficiary in three other variable interest entities, which are consolidated and reflected in our consolidated financial statements.

Our proportionate share of outstanding debt related to our unconsolidated partnerships is summarized below (dollars in thousands):

| Name                  | Ownership<br>Percentage | Interest Rate<br>(2) | Principal Amount (1) |                         | Maturity Date        |
|-----------------------|-------------------------|----------------------|----------------------|-------------------------|----------------------|
|                       |                         |                      | June 30,<br>2009     | December<br>31,<br>2008 |                      |
| PREI I and PREI II(3) | 20%                     | 3.82%                | \$ 40,650            | \$ 72,811               | February 10,<br>2011 |
| PREI I(4)             | 20%                     | 4.10%                | 33,634               | 28,706                  | August 13,<br>2010   |
| McKellar Court(5)     | 21%                     | 4.63%                | 2,159                | 2,175                   | January 1,<br>2010   |
| Total                 |                         |                      | \$ 76,443            | \$ 103,692              |                      |

(1) Amount represents our proportionate

share of the total outstanding indebtedness for each of the unconsolidated partnerships.

- (2) Effective or weighted average interest rate of the outstanding indebtedness as of June 30, 2009.
- (3) Amount represents our proportionate share of the total draws outstanding under a secured acquisition and interim loan facility, which bears interest at a LIBOR-indexed variable-rate. The secured acquisition and interim loan facility was utilized by both PREI I LLC and PREI II LLC to acquire a portfolio of properties (initial borrowings of approximately \$427.0 million) on April 4, 2007 (see Note 8 in the accompanying consolidated financial statements). On

February 11, 2009, our PREI joint ventures jointly refinanced the outstanding balance of the secured acquisition and interim loan facility, or approximately \$364.1 million, with the proceeds of a new loan totaling \$203.3 million and members capital contributions funding the balance due. The new loan bears interest at a rate equal to, at the option of our PREI joint ventures, either (a) reserve adjusted LIBOR plus 350 basis points or (b) the higher of (i) the prime rate then in effect, (ii) the federal funds rate then in effect plus 50 basis points or (iii) one-month LIBOR plus 450 basis points, and requires interest only monthly payments until the maturity date, February 10, 2011.

- (4) Amount represents our proportionate share of a secured construction loan, which bears interest at a LIBOR-indexed variable-rate. The secured construction loan was executed by a wholly owned subsidiary of PREI I LLC in connection with the construction of the 650 East Kendall Street property (initial borrowings of \$84.0 million on February 13, 2008 were used in part to repay a portion of the secured acquisition and interim loan facility). The remaining balance is being utilized to fund construction costs at the property.
- (5) Amount represents our proportionate share of the principal balance outstanding on a mortgage note payable, which is secured by the McKellar Court

property  
(excluding  
\$66,000 of  
unamortized  
debt premium).

**Table of Contents****Cash Distribution Policy**

We elected to be taxed as a REIT under the Code commencing with our taxable year ended December 31, 2004. To qualify as a REIT, we must meet a number of organizational and operational requirements, including the requirement that we distribute currently at least 90% of our ordinary taxable income to our stockholders. It is our intention to comply with these requirements and maintain our REIT status. As a REIT, we generally will not be subject to corporate federal, state or local income taxes on taxable income we distribute currently (in accordance with the Code and applicable regulations) to our stockholders. If we fail to qualify as a REIT in any taxable year, we will be subject to federal, state and local income taxes at regular corporate rates and may not be able to qualify as a REIT for subsequent tax years. Even if we qualify as a REIT for federal income tax purposes, we may be subject to certain state and local taxes on our income and to federal income and excise taxes on our undistributed taxable income, *i.e.*, taxable income not distributed in the amounts and in the time frames prescribed by the Code and applicable regulations thereunder.

In April 2009, in an effort to maintain financial flexibility in light of the current capital markets environment, we reset our annual dividend rate on shares of our common stock to \$0.44 per share, starting in the second quarter of 2009. While this change in our dividend level represents our current expectation, the actual dividend payable will be determined by our board of directors based upon the circumstances at the time of declaration and, as a result, the actual dividend payable may vary from such expected amount. The decision to declare and pay dividends on shares of our common stock in the future, as well as the timing, amount and composition of any such future dividends, will be at the sole discretion of our board of directors in light of conditions then existing, including our earnings, financial condition, capital requirements, debt maturities, the availability of debt and equity capital, applicable REIT and legal restrictions and the general overall economic conditions and other factors.

The following table provides historical dividend information for our common and preferred stock for the prior two fiscal years and the six months ended June 30, 2009:

| <b>Quarter Ended</b> | <b>Date Declared</b> | <b>Date Paid</b> | <b>Dividend<br/>per Common Share</b> | <b>Dividend<br/>per Preferred Share</b> |
|----------------------|----------------------|------------------|--------------------------------------|---|
| March 31, 2007       | March 15, 2007       | April 16, 2007   | \$ 0.3100                            | \$ 0.45582                              |
| June 30, 2007        | June 15, 2007        | July 16, 2007    | 0.3100                               | 0.45582                                 |
| September 30, 2007   | September 14, 2007   | October 15, 2007 | 0.3100                               | 0.46094                                 |
| December 31, 2007    | December 12, 2007    | January 15, 2008 | 0.3100                               | 0.46094                                 |
| March 31, 2008       | March 14, 2008       | April 15, 2008   | 0.3350                               | 0.46094                                 |
| June 30, 2008        | June 16, 2008        | July 15, 2008    | 0.3350                               | 0.46094                                 |
| September 30, 2008   | September 15, 2008   | October 15, 2008 | 0.3350                               | 0.46094                                 |
| December 31, 2008    | December 15, 2008    | January 15, 2009 | 0.3350                               | 0.46094                                 |
| March 31, 2009       | March 16, 2009       | April 15, 2009   | 0.3350                               | 0.46094                                 |
| June 30, 2009        | June 15, 2009        | July 15, 2009    | 0.1100                               | 0.46094                                 |

**Inflation**

Some of our leases contain provisions designed to mitigate the adverse impact of inflation. These provisions generally increase rental rates during the terms of the leases either at fixed-rates or indexed escalations (based on the Consumer Price Index or other measures). We may be adversely impacted by inflation on the leases that do not contain indexed escalation provisions. In addition, most of our leases require the tenant to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes and insurance. This may reduce our exposure to increases in costs and operating expenses resulting from inflation, assuming our properties remain leased and tenants fulfill their obligations to reimburse us for such expenses.

Portions of our unsecured line of credit and secured term loan bear interest at a variable-rate, which will be influenced by changes in short-term interest rates, and will be sensitive to inflation.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Our future income, cash flows and fair-values relevant to financial instruments depend upon prevailing market interest rates. Market risk is the exposure to loss resulting from changes in interest rates, foreign currency exchange rates,

commodity prices and equity prices. The primary market risk to which we believe we are exposed is interest rate risk. Many factors, including governmental monetary and tax policies, domestic and international economic and political considerations and other factors that are beyond our control contribute to interest rate risk.



**Table of Contents**

As of June 30, 2009, our consolidated debt consisted of the following (dollars in thousands):

|                               | <b>Principal Balance<br/>(1)</b> | <b>Percent of<br/>Total Debt</b> | <b>Effective<br/>Interest<br/>Rate at<br/>June 30, 2009</b> |
|-------------------------------|----------------------------------|----------------------------------|---|
| Fixed interest rate (2)       | \$ 820,841                       | 60.2%                            | 6.64%   |
| Variable interest rate (3)    | 542,404                          | 39.8%                            | 4.61%   |
| Total/effective interest rate | \$ 1,363,245                     | 100.0%                           | 5.85%   |

(1) Principal balance includes only consolidated indebtedness.

(2) Includes 15 mortgage notes payable secured by certain of our properties (including \$7.9 million of unamortized premium) and our exchangeable senior notes (including \$4.3 million of unamortized debt discount).

(3) Includes our unsecured line of credit and secured term loan, which bear interest based on a LIBOR-indexed variable interest rate, plus a credit spread. However, we are

party to two interest rate swaps, which were intended to have the effect of initially fixing the interest rates on \$150.0 million of our variable-rate borrowings at 5.8% (based on the applicable credit spreads for the underlying debt at June 30, 2009) until the interest rate swaps expire in August 2011. We have also entered into an interest rate swap agreement that is intended to fix the interest rate on the entire \$250.0 million outstanding balance of the secured term loan at a rate of 5.8% (including the credit spread for the \$250.0 million secure term loan at June 30, 2009) until the interest rate swap expires in 2010.

To determine the fair-value of our outstanding consolidated and proportionate share of unconsolidated indebtedness, the fixed-rate debt is discounted at a rate based on an estimate of current lending rates, assuming the debt is outstanding through maturity and considering the notes collateral. At June 30, 2009, the fair-value of our consolidated and proportionate share of unconsolidated fixed-rate debt was estimated to be \$777.2 million compared to the net carrying value of \$823.1 million (includes \$3.6 million of unamortized premiums, net of discounts, with our proportionate share of the debt premium related to our McKellar Court partnership). We do not believe that the interest rate risk represented by our fixed-rate debt was material as of June 30, 2009 in relation to total assets of

\$3.3 billion and equity market capitalization of \$1.3 billion of our common stock, operating partnership and LTIP units, and preferred stock.

Based on the outstanding unhedged balances of our unsecured line of credit and our proportionate share of the outstanding balances for the PREI limited liability companies' secured construction loan at June 30, 2009, a 1% change in interest rates would change our interest cost by approximately \$1.5 million per year. This amount was determined by considering the impact of hypothetical interest rates on our financial instruments. This analysis does not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of the magnitude discussed above, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, this analysis assumes no changes in our financial structure.

In order to modify and manage the interest rate characteristics of our outstanding debt and to limit the effects of interest rate risks on our operations, we may utilize a variety of financial instruments, including interest rate swaps, caps and treasury locks in order to mitigate our interest rate risk on a related financial instrument. The use of these types of instruments to hedge our exposure to changes in interest rates carries additional risks, including counterparty credit risk, the enforceability of hedging contracts and the risk that unanticipated and significant changes in interest rates will cause a significant loss of basis in the contract. To limit counterparty credit risk we will seek to enter into such agreements with major financial institutions with high credit ratings. There can be no assurance that we will be able to adequately protect against the foregoing risks and will ultimately realize an economic benefit that exceeds the related amounts incurred in connection with engaging in such hedging activities. We do not enter into such contracts for speculative or trading purposes.

#### **ITEM 4. CONTROLS AND PROCEDURES**

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Also, we have investments in unconsolidated entities. As we manage these entities, our disclosure controls and procedures with respect to such entities are essentially consistent with those we maintain with respect to our consolidated entities.

As required by Securities and Exchange Commission Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.

There has been no change in our internal control over financial reporting during the quarter ended June 30, 2009 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

**Table of Contents**

**PART II OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

Although we are involved in legal proceedings arising in the ordinary course of business, we are not currently a party to any legal proceedings nor, to our knowledge, is any legal proceeding threatened against us that we believe would have a material adverse effect on our financial position, results of operations or liquidity.

**ITEM 1A. RISK FACTORS**

Investing in our common stock involves risks. Our annual report on Form 10-K for the year ended December 31, 2008 includes detailed discussions of our risk factors under the heading Part I, Item 1A. Risk Factors. Set forth below are certain changes from the risk factors previously disclosed in our annual report on Form 10-K as a result of certain events that occurred during the second quarter of 2009. You should carefully consider the risk factors discussed in our annual report on Form 10-K, as well as the other information in this report, before deciding whether to invest in shares of our common stock. The occurrence of any of the risks discussed in our annual report on Form 10-K or this report could harm our business, financial condition, results of operations or growth prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

**Risks Related to the Ownership of Our Stock**

***Our distributions to stockholders may decline at any time.***

We may not continue our current level of distributions to stockholders. Our board of directors will determine future distributions based on a number of factors, including:

- cash available for distribution,
- operating results,
- our financial condition, especially in relation to our anticipated future capital needs,
- then current expansion plans,
- the distribution requirements for REITs under the Code, and
- other factors our board deems relevant.

In April 2009, in an effort to maintain financial flexibility in light of the current capital markets environment, we reset our annual dividend rate on shares of our common stock to \$0.44 per share, starting in the second quarter of 2009. While this change in our dividend level represents our current expectation, the actual dividend payable will be determined by our board of directors based upon the circumstances at the time of declaration and, as a result, the actual dividend payable may vary from such expected amount. The decision to declare and pay dividends on shares of our common stock in the future, as well as the timing, amount and composition of any such future dividends, will be at the sole discretion of our board of directors in light of conditions then existing, including our earnings, financial condition, capital requirements, debt maturities, the availability of debt and equity capital, applicable REIT and legal restrictions and the general overall economic conditions and other factors. Any change in our dividend policy could have a material adverse effect on the market price of our common stock.

**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**Table of Contents****ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

Our annual meeting of stockholders was held on May 27, 2009. The only matters voted upon at our annual meeting consisted of the election of seven of our directors to serve until the next annual meeting of stockholders and until their successors are duly elected and qualify, the ratification of the selection of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2009, and the approval of the amendment and restatement of our 2004 Incentive Award Plan, which included increasing the number of shares of our common stock reserved for issuance thereunder from 2,500,000 shares to 5,340,000 shares. Stockholders elected the directors at our annual meeting by the following vote:

|                         | <b>Votes For</b> | <b>Votes Withheld</b> |
|-------------------------|------------------|-----------------------|
| Alan D. Gold            | 68,849,994       | 739,221               |
| Gary A. Kreitzer        | 68,488,052       | 1,101,163             |
| Barbara R. Cambon       | 69,114,881       | 474,334               |
| Edward A. Dennis, Ph.D. | 69,138,866       | 450,349               |
| Richard I. Gilchrist    | 69,106,185       | 483,030               |
| Theodore D. Roth        | 69,205,859       | 383,356               |
| M. Faye Wilson          | 69,187,178       | 402,037               |

Stockholders ratified the selection of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2009 (69,142,175 votes for, 400,447 against and 46,592 abstained).

Stockholders approved the amendment and restatement of our 2004 Incentive Award Plan (51,639,803 votes for, 14,138,555 against and 51,864 abstained).

**ITEM 5. OTHER INFORMATION**

None.

**ITEM 6. EXHIBITS**

| <b>Exhibit<br/>Number</b> | <b>Description of Exhibit</b>   |
|---------------------------|---|
| 3.1                       | Articles of Amendment of BioMed Realty Trust, Inc.(1)   |
| 10.1                      | 2004 Incentive Award Plan of BioMed Realty Trust, Inc. and BioMed Realty, L.P. (as Amended and Restated Effective May 27, 2009).(2)   |
| 31.1                      | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 31.2                      | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 32.1                      | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

(1) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K,

filed with the  
Securities and  
Exchange  
Commission on  
May 12, 2009.

- (2) Incorporated  
herein by  
reference to  
BioMed Realty  
Trust, Inc. s  
Current Report  
on Form 8-K,  
filed with the  
Securities and  
Exchange  
Commission on  
June 1, 2009.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BioMed Realty Trust, Inc.

/s/ ALAN D. GOLD

Alan D. Gold

Chairman of the Board and Chief Executive  
Officer

(Principal Executive Officer)

/s/ KENT GRIFFIN

Kent Griffin

President, Chief Operating Officer and  
Chief Financial Officer

(Principal Financial Officer)

Dated: July 30, 2009

**Table of Contents**

**EXHIBIT INDEX**

| <b>Exhibit<br/>Number</b> | <b>Description of Exhibit</b>   |
|---------------------------|---|
| 3.1                       | Articles of Amendment of BioMed Realty Trust, Inc.(1)   |
| 10.1                      | 2004 Incentive Award Plan of BioMed Realty Trust, Inc. and BioMed Realty, L.P. (as Amended and Restated Effective May 27, 2009).(2)   |
| 31.1                      | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 31.2                      | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 32.1                      | Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |

(1) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 12, 2009.

(2) Incorporated herein by reference to BioMed Realty Trust, Inc.'s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 1, 2009.